<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55732</article-id><article-id pub-id-type="doi">10.7554/eLife.55732</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Novel C1q receptor-mediated signaling controls neural stem cell behavior and neurorepair</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-174022"><name><surname>Benavente</surname><given-names>Francisca</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8245-2673</contrib-id><email>fbenaven@uci.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38520"><name><surname>Piltti</surname><given-names>Katja M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177396"><name><surname>Hooshmand</surname><given-names>Mitra J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6159-6934</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177397"><name><surname>Nava</surname><given-names>Aileen A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2053-6713</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177398"><name><surname>Lakatos</surname><given-names>Anita</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177399"><name><surname>Feld</surname><given-names>Brianna G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185964"><name><surname>Creasman</surname><given-names>Dana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177400"><name><surname>Gershon</surname><given-names>Paul D</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-38524"><name><surname>Anderson</surname><given-names>Aileen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8203-8891</contrib-id><email>aja@uci.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Sue and Bill Gross Stem Cell Research Center</institution><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Anatomy and Neurobiology</institution><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Center of Regenerative Medicine, Facultad de Medicina, Universidad del Desarrollo</institution><addr-line><named-content content-type="city">Santiago</named-content></addr-line><country>Chile</country></aff><aff id="aff4"><label>4</label><institution>Institute for Memory Impairments and Neurological Disorders</institution><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Bridges to Stem Cell Research Program (BSCR), California State University</institution><addr-line><named-content content-type="city">Long Beach</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Physical Medicine and Rehabilitation</institution><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Molecular Biology &amp; Biochemistry, UC-Irvine</institution><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pera</surname><given-names>Martin</given-names></name><role>Reviewing Editor</role><aff><institution>The Jackson Laboratory</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Senior Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>07</day><month>09</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e55732</elocation-id><history><date date-type="received" iso-8601-date="2020-03-09"><day>09</day><month>03</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-07-20"><day>20</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Benavente et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Benavente et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55732-v2.pdf"/><abstract><p>C1q plays a key role as a recognition molecule in the immune system, driving autocatalytic complement cascade activation and acting as an opsonin. We have previously reported a non-immune role of complement C1q modulating the migration and fate of human neural stem cells (hNSC); however, the mechanism underlying these effects has not yet been identified. Here, we show for the first time that C1q acts as a functional hNSC ligand, inducing intracellular signaling to control cell behavior. Using an unbiased screening strategy, we identified five transmembrane C1q signaling/receptor candidates in hNSC (CD44, GPR62, BAI1, c-MET, and ADCY5). We further investigated the interaction between C1q and CD44 , demonstrating that CD44 mediates C1q induced hNSC signaling and chemotaxis in vitro, and hNSC migration and functional repair in vivo after spinal cord injury. These results reveal a receptor-mediated mechanism for C1q modulation of NSC behavior and show that modification of C1q receptor expression can expand the therapeutic window for hNSC transplantation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>complement C1q</kwd><kwd>neural stem cell transplants</kwd><kwd>spinal cord injury</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005191</institution-id><institution>Craig H. Neilsen Foundation</institution></institution-wrap></funding-source><award-id>CHN-316291</award-id><principal-award-recipient><name><surname>Anderson</surname><given-names>Aileen</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001305</institution-id><institution>Christopher and Dana Reeve Foundation</institution></institution-wrap></funding-source><award-id>AAC-2013(5)</award-id><principal-award-recipient><name><surname>Anderson</surname><given-names>Aileen</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1S10OD016328-01</award-id><principal-award-recipient><name><surname>Gershon</surname><given-names>Paul D</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Complement C1q directly drives the behavior of human neural stem cells via a classical receptor signaling mechanism modulating their capacity for functional integration in vivo.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Therapeutic transplantation of human neural stem cells (hNSC) offers a promising approach for neural repair in neurodegenerative disorders and central nervous system (CNS) injuries. While the immunomodulatory effect of donor stem cells on the host has been extensively studied (<xref ref-type="bibr" rid="bib67">Tena and Sachs, 2014</xref>; <xref ref-type="bibr" rid="bib54">Pluchino et al., 2005</xref>; <xref ref-type="bibr" rid="bib75">Zhang et al., 2013</xref>) the converse effect of the host immune-microenvironment on donor stem cells has received little attention. We have previously shown that polymorphonuclear neutrophils (PMNs), which infiltrate the spinal cord at acute time points post trauma (<xref ref-type="bibr" rid="bib7">Beck et al., 2010</xref>), alter the responses of donor cells after acute spinal cord injury (SCI) transplantation. Specifically, systemic immunodepletion of PMNs inhibits donor hNSC astrogliogenesis and rescues the capacity of donor cells to promote functional repair after acute transplantation into the SCI microenvironment (<xref ref-type="bibr" rid="bib42">Nguyen et al., 2017</xref>). These data demonstrate that functional integration of transplanted stem cells is dependent, at least in part, on interactions between donor cells and cellular/molecular cues in the host microenvironment. We also demonstrated that secreted factors derived from two distinct immune populations, PMN and macrophages/microglia (Mφ), drive hNSC migration and lineage selection (fate) and identified complement C1q and C3a as molecular mediators (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). These data highlight the importance of cues from the host inflammatory microenvironment in modulating NSC behavior, and identify a significant in vitro and in vivo role for complement C1q in modulating NSC cell behavior.</p><p>The complement system is an enzymatic cascade of proteins that plays a crucial role as the first line of defense against pathogens as it contributes to both innate and adaptive immune responses (<xref ref-type="bibr" rid="bib18">Dunkelberger and Song, 2010</xref>). C1q is the recognition molecule of the classical pathway of complement activation. The traditional role of C1q in the immune system is to recognize and bind to antigen-antibody immune complexes, pathogens, lipids, and proteins accumulated during apoptosis or present on cell debris, initiating autocatalytic activation of the complement cascade and/or driving debris clearance by phagocytic immune populations. Recently, C1q has been found to act in non-traditional roles (<xref ref-type="bibr" rid="bib50">Peterson and Anderson, 2014</xref>). In the CNS, C1q mediates the elimination of low activity presynaptic terminals by microglia (<xref ref-type="bibr" rid="bib63">Stephan et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Presumey et al., 2017</xref>) and modulates axon growth and guidance by masking myelin-associated glycoprotein-mediated growth inhibitory signaling (<xref ref-type="bibr" rid="bib49">Peterson et al., 2015</xref>). In the muscle, C1q in C1 complex activates canonical Wnt signaling via conformation-induced activation of C1s serine protease activity, promoting age-associated decline in regeneration (<xref ref-type="bibr" rid="bib38">Naito et al., 2012</xref>). In both cases, these activities are independent of complement cascade activation but remain consistent with the recognition functions of C1q in the immune system (<xref ref-type="bibr" rid="bib11">Botto et al., 1998</xref>; <xref ref-type="bibr" rid="bib37">Mevorach et al., 1998</xref>; <xref ref-type="bibr" rid="bib40">Nauta et al., 2002</xref>). Additionally, however, C1q induces ERK signaling in fetal cytotrophoblasts (<xref ref-type="bibr" rid="bib1">Agostinis et al., 2010</xref>), and binds discoidin domain receptor 1 (DDR1), directly activating mitogen-activated protein kinases and PI3K/Akt in hepatocellular tumor cells (<xref ref-type="bibr" rid="bib34">Lee et al., 2018</xref>). This result suggests that C1q could play additional non-traditional roles, functioning as a ligand that can initiate cell signaling and/or directly interact with a transmembrane receptor to mediate cell signaling. Supporting this notion in CNS cells, C1q in the absence of other complement components induces neuronal-gene expression critical for cell survival in vitro (<xref ref-type="bibr" rid="bib8">Benoit and Tenner, 2011</xref>), and our recent data link C1q to direct effects on NSC function and signaling (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>).</p><p>We hypothesize that there is receptor-mediated communication between the host immune system and endogenous and/or donor NSC in the injured, diseased, or aged CNS that is mediated by C1q. Consistent with such a role, C1q protein/mRNA increases and persists locally in the CNS after injury and in aging/disease as a result of disruption to the blood–brain barrier and local synthesis by invading and resident inflammatory cells (<xref ref-type="bibr" rid="bib50">Peterson and Anderson, 2014</xref>; <xref ref-type="bibr" rid="bib41">Nguyen et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Dunkelberger and Song, 2010</xref>; <xref ref-type="bibr" rid="bib4">Anderson et al., 2004</xref>). In this study, we test whether C1q directly modulates NSC behavior through cell surface protein interactions and receptor-mediated cell signaling transduction mechanisms. We show for the first time that C1q activates specific intracellular signaling pathways in NSC to modulate NSC behavior. Using an unbiased screening strategy, we identify five novel transmembrane C1q signaling/receptor candidates in NSC, and define specific functions for the first of these, CD44, establishing the biological relevance of C1q-receptor interactions. These findings reveal an important role of complement C1q in modulating NSC behavior and identify a novel element in the understanding of the neuro-immune interface and NSC biology.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>C1q induces specific activation of intracellular signaling pathways on hNSC</title><p>We investigated the effects of C1q on intracellular signaling in hNSC by testing three physiological C1q concentrations that are produced by PMN [28 ng/mL ≅ 0.1 nM] (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>), Mφ [400 ng/mL ≅ 1.0 nM] (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>), or present in plasma. Reported levels of circulating C1q range between 40 and 120 µg/mL (<xref ref-type="bibr" rid="bib17">Dillon et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Delamarche et al., 1988</xref>; <xref ref-type="bibr" rid="bib72">Yonemasu et al., 1978</xref>); in this study, we used [80 µg/mL ≅ 200 nM]. hNSC were treated with purified human C1q for 15, 30, and 60 min, and activation of intracellular signaling pathways assessed using a quantitative phosphoarray analysis that can simultaneously detect 18 phosphorylated proteins that are part of well-described intracellular signaling pathways (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; a 1.5-fold increase was defined as the minimum threshold for positive response). Phosphoarray analysis demonstrated rapid activation of specific and selective signaling pathways after C1q treatment, with MAPK/ERK signaling showing the most robust effect at all tested C1q concentrations. C1q at 200 nM also significantly and selectively activated PI3K signaling, identified by p-Akt and P70 S6 kinase, as well as P53. Phosphoarray results were confirmed using western blot for intracellular activation of p-Akt and p-ERK after 60 min of C1q exposure (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). These data demonstrate rapid C1q-mediated activation of specific intracellular signaling pathways, consistent with a receptor-mediated mechanism.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>C1q induces intracellular signaling activation in hNSC.</title><p>(<bold>A</bold>) Phosphoarray analysis quantification of hNSC exposed to C1q [0.1 nM], [1.0 nM], or [200 nM] concentrations for 15, 30, or 60 min. Data show mean ± SEM (N = 3 biological replicates per condition) for quantified optical intensity, normalized to control (dashed line = 1). In addition to statistical analysis, using one-sample t-test (*p≤0.05, **p≤0.01, ***p≤0.001), a minimum threshold of 1.5-fold activation (dashed line) was set for statistical significance. (<bold>B</bold>) ERK and Akt activation was verified using western blot in lysates from hNSC exposed to C1q [0.1 nM], [1.0 nM], or [200 nM] concentrations for 60 min. p-ERK and p-Akt band intensities were normalized to β-actin. Data show mean ± SEM (N = 3 biological replicates per condition) for quantified optical intensity normalized to control (dashed line). Statistical analysis using one-sample t-test (NS, not significant; *p≤0.05, **p≤0.01, ***p≤0.001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>C1q induces intracellular signaling activation in hNSC.</title><p>(<bold>A</bold>) Representative images and numerical scheme of phosphoarray analysis of hNSC exposed to control media or C1q [0.1 nM; 1.0 nM; 200 nM] for 30 min. Array positions indicated for p-ERK (blue), p-Akt thr308 (orange), and ser473 (red). (<bold>B</bold>) Orientation and positions of the intracellular signaling proteins (in duplicate) assayed by phosphoarray: number 3 (blue, p-ERK); number 6 (orange, p-Akt thr308); and number 7 (red, p-Akt ser473). (<bold>C</bold>) Complete list of targets, intracellular proteins, and modifications tested by phosphoarray. Phosphoarray by PathScan Intracellular signaling array kit as described under Methods (Catalog #7744, Cell Signaling Technology).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Unbiased screening strategy for cell surface C1q-binding partners on hNSC identifies five novel candidates</title><p>Based on the observation of C1q-induced intracellular signaling pathway activation, we followed an unbiased screening strategy to identify cell surface proteins on hNSC that interact with C1q. In a first approach, we used a far-western blot strategy to qualitatively establish the ability of C1q to interact with hNSC cell surface proteins (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We first verified whether C1q could bind a multitude of intracellular proteins in total protein lysates in this assay, consistent with the conventional role of C1q as a recognition molecule of the classical complement pathway. Next, we tested C1q binding, specifically, in the cell surface fraction. In contrast to the total protein fraction, we identified few bands, suggesting that C1q interacts specifically with a small number of cell surface binding partners on hNSC.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Unbiased screening for cell surface C1q-binding partners on hNSC identifies five novel signaling candidates.</title><p>(<bold>A</bold>) C1q binds specifically to cell surface proteins in hNSC. Far-western blot reveals C1q binding interactions in hNSC protein fractions derived from either total (multiple bands) or cell surface (few bands) isolates. Exclusion of C1q (no C1q control) reveals no anti-C1q staining. (<bold>B</bold>) Silver stain (left) and anti-C1q western blot (right) analysis in C1q pull-downs with hNSC total protein lysates. Conditions: (I) column + C1q (bait) and no total protein lysate (prey), verifying C1q attachment to the column; (II) column + total protein lysate (prey) and no C1q (bait), confirming the absence of nonspecific protein binding to the column; (III) column + C1q (bait) + total protein lysate (prey), identifying multiple bands associated with C1q. (<bold>C</bold>) Experimental scheme for identification of C1q binding partners on hNSC cell surface using a cell surface crosslinking strategy followed by pull-down and mass spectrometry analysis. (<bold>D</bold>) Cell surface-C1q crosslinking using the strategy from (<bold>C</bold>) identifies five novel membrane-bound signaling candidates. RT-PCR analysis in hNSC and positive control samples (+CTRL, human universal RNA) demonstrates the positive expression of each target signaling candidate by hNSC. (<bold>E</bold>) Human embryonic cortex single-cell RNA-seq dataset analysis verifies C1q candidate receptor expression on NSC. Heatmap clustered on the gene expression of glia cell type identity gene markers and C1q candidate receptors gene reveals a subset of glia cells that express the candidate receptor genes. Glia cells were processed and categorized into NSC (radial glia), astrocyte precursor cells (APC)/astrocytes, oligoprogenitors (OPCs), and oligodendrocytes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Biochemical analysis of C1q and biotinylated-C1q.</title><p>(<bold>A</bold>) Western blot of purified unmodified C1q (C1q) and biotinylated C1q (C1q-Biot) using anti-C1q antibody. (<bold>B</bold>) Gel electrophoresis of C1q and C1q-Biot demonstrates that avidin-biotin-peroxidase complex (ABC) (Vector Laboratories) followed by enhanced chemiluminescence (ECL) reaction with horseradish peroxidase (HRP) substrate recognizes only biotinylated C1q. (<bold>C-E</bold>) C1q and C1q-Biot show similar interaction patterns in far-western blot. (<bold>C</bold>) Far-westernblot reveals similar binding patterns of naive (C1q, left panel) or biotinylated C1q (C1q-Biot, middle panel) with proteins from hNSC total protein lysates. Control membranes were incubated without C1q (No C1q, right panel). Bound C1q was identified by immunodetection. (<bold>D-E</bold>) Competitive binding of biotinylated-C1q and naive-C1q demonstrates interaction specificity. (<bold>D</bold>) Far-westernblot was performed with hNSC total protein lysates and C1q-Biot. Membranes were then differentially washed with either TBS-T (control) or TBS-T + unmodified C1q, to compete with C1q-Biot for protein interactions. Bound C1q-Biot was identified by ABC-ECL reaction. Control membranes were incubated without C1q (right panel). (<bold>E</bold>) Relative optical density analysis reveals that washes with unmodified-C1q decreased C1q-Biot binding indicating the specificity of the interaction. Data show mean ± SEM of bound C1q relative optic intensity normalized to control (TBS-T washes; dashed line). Statistical analysis using one-sample t-test for comparison with control (*p=0.0398).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig2-figsupp1-v2.tif"/></fig></fig-group><p>We sought to identify cell surface C1q binding partners using mass spectrometry nanoLC-MS/MS analysis of samples generated by two parallel strategies: 1) pull-down of whole cell hNSC protein isolates with biotinylated C1q immobilized on a streptavidin column; 2) pull-down of hNSC membrane protein fraction isolates generated after incubation and cross-linking of live hNSC with C1q. For the first approach, after validating that biotinylated and non-biotinylated C1q shared similar binding patterns (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>) and binding specificity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D,E</xref>), total protein extract was incubated with immobilized C1q followed by a stringent wash protocol to minimize detection of nonspecific interactions. Bound proteins were eluted and analyzed using SDS-PAGE followed by silver staining (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and by nanoLC-MS/MS, which identified over 400 protein families. However, consistent with the far-western blot data and known interactions between C1q and intracellular constituents, few of these were known cell surface proteins.</p><p>For the second approach, we designed a novel strategy to selectively identify cell surface protein interactions. A critical limitation of both far-western blots and conventional pull-down assays is that these experiments are performed with denatured proteins, resulting in 3D structure loss. Our second approach targeted assessment of C1q-hNSC cell surface protein interaction in a biologically relevant setting where the 3D structure of ligand and candidate receptors is maintained. To accomplish this, cell surface interactions were initiated in live cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Monolayer hNSC were incubated with purified human C1q followed by cross-linking bound C1q to interacting proteins using a cell impermeable cross-linker (Sulfo EGS) with a spacer arm of 16.1 A° to cross-link only closely interacting proteins. Membrane proteins cross-linked with C1q were then extracted, pulled-down with biotinylated specific anti-C1q antibody, and bound proteins eluted and analyzed using nanoLC-MS/MS. This approach identified a short list of five known transmembrane proteins representing novel candidate C1q receptor and signaling protein interactions (<xref ref-type="fig" rid="fig2">Figure 2D</xref>): CD44, GPR62, BAI1, c-MET, and ADCY5. RT-PCR analysis confirmed positive expression of these five candidates in hNSC (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). To confirm in vivo expression of the identified candidates, we evaluated published single-cell RNAseq data (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) from the human embryonic cortex at gestational weeks' 22–23 (<xref ref-type="bibr" rid="bib19">Fan et al., 2018</xref>). These data show expression in the NSC population during human development, as well as the emergence of cell type-specific expression patterns consistent with the published literature for these candidates (<xref ref-type="bibr" rid="bib76">Zhang et al., 2014</xref>), for example, the expression of CD44 in maturing astrocytes (<xref ref-type="bibr" rid="bib35">Liu et al., 2004</xref>).</p><p>C1q–signaling candidate protein interactions were validated using proximity ligation assay (PLA), in which positive fluorescence (red punctae) indicates direct binding (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). A quantitative comparison of protein interaction was performed by analyzing the number of fluorescent punctae per cell. PLA validation was performed with a negative mis-matched ligand control C1q-C3aR (<xref ref-type="fig" rid="fig3">Figure 3B,C</xref>) and a positive matched ligand control C3a-C3aR (<xref ref-type="fig" rid="fig3">Figure 3D,E</xref>). <xref ref-type="fig" rid="fig3">Figure 3F–O</xref> show representative images of PLA detection of C1q-CD44, C1q-GPR62, C1q-BAI1, C1q-c-MET, and C1q-ADCY5 interaction, respectively, as well as quantification of PLA binding for each signaling/receptor candidate. These data identify and validate C1q interaction with identified receptor/signaling candidates on hNSC, all of which represent novel binding partners.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Proximity Ligation Assay (PLA) verifies C1q binding with five novel signaling candidates.</title><p>(<bold>A</bold>) In proximity ligation assays quantifiable positive red fluorescent punctae are obtained only when two target proteins are interacting nearby (&lt;30 nm). (<bold>B</bold>) PLA validation showing a representative image from a mis-matched ligand-receptor negative control (C1q-C3aR); quantification in (<bold>C</bold>). (<bold>D</bold>) PLA validation showing a representative image from a matched ligand-receptor positive control (C3a-C3aR); quantification in (<bold>E</bold>). PLA representative images and quantification of C1q with novel signaling candidates: (<bold>F,G</bold>) C1q-CD44; (<bold>H,I</bold>) C1q-GPR62; (<bold>J,K</bold>) C1q-BAI1; (<bold>L,M</bold>) C1q-c-MET; and (<bold>N,O</bold>) C1q-ADCY5. Membrane staining (green) shown with Alexa 488 conjugated wheat germ agglutinin (WGA). Scale bars 10 µm. Graphs represent quantification of the average number of fluorescent punctae/cell in 13 random pictures/experiment (n = 2 biological replicates; mean ± SEM). Statistical analysis of PLA punctae was significant via one-way ANOVA for all signaling candidates at p&lt;0.05 and was followed by Tukey’s post-hoc t-tests as indicated (NS, not significant; *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001), no significant difference (ANOVA p=0.184) was identified in the negative control condition.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig3-v2.tif"/></fig><p>GPR62 and BAI1 are classical G-protein coupled receptors (GPCRs). Brain angiogenesis inhibitor protein 3 (BAI3) is a BAI1 homolog that has already been shown to bind to C1q and C1q like proteins in the CNS (<xref ref-type="bibr" rid="bib10">Bolliger et al., 2011</xref>), supporting our findings from the candidate screening strategy. GPR62 is an orphan receptor that has no previously identified ligands (<xref ref-type="bibr" rid="bib33">Lee et al., 2001</xref>). c-Met is a receptor tyrosine kinase (RTK) for which hepatocyte growth factor is the only known ligand (<xref ref-type="bibr" rid="bib45">Organ and Tsao, 2011</xref>). ADCY5 belongs to the family of membrane-bound adenylate cyclases (AC) that modulate downstream signaling effectors such as cAMP-dependent protein kinase A (PKA) (<xref ref-type="bibr" rid="bib59">Sassone-Corsi, 2012</xref>). Finally, CD44 is a multi-ligand, multifunctional transmembrane glycoprotein that controls cellular signaling through interactions with other cell surface receptors, including RTKs (e.g., c-Met) (<xref ref-type="bibr" rid="bib46">Orian-Rousseau et al., 2002</xref>), GPCRs (e.g., CXCR4) (<xref ref-type="bibr" rid="bib22">Fuchs et al., 2013</xref>), and Wnt-induced beta-catenin/LRP6 (<xref ref-type="bibr" rid="bib60">Schmitt et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Orian-Rousseau and Schmitt, 2015</xref>).</p><p>We hypothesized that selected C1q signaling/receptor candidates may have specific in vitro and in vivo functions; for example, mediation of C1q induced migration vs. direction of hNSC fate or proliferation. If different C1q signaling/receptor candidates mediate different functions, these functions could potentially be linked to the activation of specific intracellular signaling pathways in hNSC. We evaluated the functional significance of specific intracellular signaling pathways in C1q-induced chemotaxis and C1q-modulation of proliferation on hNSC using intracellular signaling pathway inhibitors focusing on: 1) pERK/MAPK inhibition because C1q induces p-ERK signaling at all tested concentrations (PD98059); 2) G-protein coupled receptor inhibition because two candidates are GPCRs (pertussis toxin, PTX); and 3) p38 MAPK inhibition as a negative control because we did not detect p38 signaling induction (SB20358). We focused on migration and proliferation to minimize the potential for toxicity due to long-term inhibitor treatment, and because we have previously established the effects of C1q administration on these hNSC responses (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). We first verified that a 48 hr exposure to the tested inhibitors did not result in toxicity as assessed by total cell number (data not shown; one-way ANOVA p=0.6226). C1q activation of p-ERK was effectively blocked by PD98059 in western blot (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>), and C1q-induced migration in transwell assays was selectively inhibited only by p-ERK inhibition (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In contrast, the effect of C1q on hNSC proliferation in BrdU incorporation assays was both p-ERK and GPCR dependent but not affected by p38 inhibition (<xref ref-type="fig" rid="fig4">Figure 4D,E</xref>). These data indicate that different signaling pathways mediate distinct effects on hNSC, consistent with the hypothesis that different receptors mediate different cellular functions.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Distinct cellular signaling pathways control different C1q induced hNSC behavior.</title><p>(<bold>A,B</bold>) Western blot analysis in cells treated with the MEK/ERK pathway inhibitor PD89059 verifies effective p-ERK inhibition in cells exposed to C1q [200 nM] for 60 min. Optical densities were normalized to untreated controls (dashed line). Statistical analysis using one-sample t-test (*p≤0.05, **p≤0.01) for comparison with control and Student’s t-test for comparison between conditions as indicated (***p≤0.001). N = 3 biological replicates. (<bold>C</bold>) C1q [200 nM] induces hNSC chemotaxis in transwell migration assays (shown also in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>), which is blocked by PD89059 inhibition of p-ERK. No effect was observed with either a GPCR inhibitor (Pertussis toxin; PTX) or p38 MAPK inhibitor (SB203580). (<bold>D,E</bold>) C1q [200 nM] decreases hNSC proliferation in vitro as analyzed by BrdU incorporation (shown also in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E–F</xref>), which is blocked by either PD89059 or PTX treatment. No effect was observed with the p38 inhibitor SB203580. (<bold>D</bold>) Representative pictures of BrdU+ cells in control hNSC or hNSC treated with C1q [200 nM] and pathway inhibitors as indicated. (<bold>E</bold>) Brdu+ nuclei quantification (%). Data shows mean ± SEM normalized to untreated controls (dashed line). Statistical analysis using one-sample t-test (NS, not significant; *p≤0.05, **p≤0.01, ***p≤0.001) for comparison with untreated controls, and using one-way ANOVA (#) p&lt;0.05 followed by Tukey’s post-hoc t-tests as indicated (NS, not significant; #p≤0.05) for comparison between conditions, N = 4 biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>C1q induces NSC motility and chemotaxis in vitro.</title><p>(<bold>A-C</bold>) Exposure to C1q in the absence of a gradient increases hNSC motility independent of concentration. Manual tracking of 20 randomly selected cells per biological replicate in live-cell imaging assay reveals that C1q increases hNSC motility as measured by track length, independent of C1q concentration. Representative image of 20 manual tracks from cells in (<bold>A</bold>) control and (<bold>B</bold>) C1q [200 nM] condition. (<bold>C</bold>) Data normalized to untreated control (dashed line). Statistical analysis using one-sample t-test (*p≤0.05, **p≤0.01; N = 3 biological replicates) for comparison with control. ANOVA analysis for comparison between groups, p=0.8682. (<bold>D</bold>) Exposure to C1q in transwell assay for analysis of chemotaxis reveals that C1q induces hNSC migration in a concentration-dependent manner, with maximal effects at 0.1 nM and 200 nM. Data normalized to untreated control (dashed line). Statistical analysis using one-sample t-test for comparison with control (*p≤0.05, **p≤0.01; n = 4 biological replicates with technical triplicates). ANOVA analysis for comparison between groups, p=0.0005. (<bold>E-F</bold>) EdU incorporation analysis reveals that C1q modulates hNSC proliferation. Representative image of Edu+ nuclei (green, white arrows) in hNSC exposed to C1q [0.1 nM], [1.0 nM], or [200 nM] for 2DIV. Scale bars 30 µm. (<bold>F</bold>) Edu+ nuclei quantification. Data shows untreated control (dashed line; mean ± SEM). Statistical analysis using one-sample t-test for comparison with control (NS = not significant p&gt;0.05, ***p≤0.001, ****p≤0.0001; 10 random images/experiment (N), N = 4 biological replicates, averaging 140 ± 60 cells/image. ANOVA analysis for comparison between groups, p≤0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>CD44 mediates C1q induced p-ERK intracellular signaling activation and migration in NSC in vitro</title><p>We focused on CD44 as an initial target through which to test the physiological role of C1q interaction with the identified hNSC receptor/signaling candidates. Given that CD44 has identified roles in p-ERK signaling (<xref ref-type="bibr" rid="bib24">Herishanu et al., 2011</xref>; <xref ref-type="bibr" rid="bib29">Kashyap et al., 2018</xref>) and glial progenitor migration (<xref ref-type="bibr" rid="bib51">Piao et al., 2013</xref>), we hypothesized that CD44 may mediate C1q-induced p-ERK activation and chemotaxis in hNSC. To test this hypothesis, we generated wildtype (WT) and knockout (KO) CD44 hNSC using CRISPR Cas9 gene editing (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s2">2</xref>), using an hNSC line generated at UCI (UCI161) for these studies. Stable selection of CD44 WT and CD44 KO hNSC populations was verified at two passages (2 weeks), four passages (4 weeks), and seven passages (7 weeks) after genetic modification using flow cytometry, (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D–G</xref>), western blot (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), and cell surface immunocytochemistry (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), respectively. Stable CRISPR-Cas9 modification and homozygous generation of CD44 WT/KO cell lines were validated by genotyping via Sanger sequencing (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). After CRISPR cas9 gene editing normal cellular karyotype was confirmed (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A–B</xref>). CD44 KO did not alter CD133+ stem cell proportion (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3C,D</xref>) or baseline hNSC proliferation in comparison with WT cells (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3E,F</xref>). Maintenance of WT and KO hNSC in differentiation media (DM) for 14 d in vitro (DIV) revealed no differences in GFAP+/βIII tubulin- astroglial lineage cells or in GFAP-/βIII tubulin+ neuronal lineage cells (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3K–S</xref>). However, CD44 KO cells exhibited a small but significant increase in nuclear Olig2+ oligodendroglial lineage cells (KO 30% vs. WT 21%, p&lt;0.0001; <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3H–J</xref>). These data demonstrate that CD44 KO cells retained normal baseline characteristics for hNSC, including multipotency.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>CD44 mediates C1q-induced ERK signaling activation and chemotaxis in hNSC in vitro.</title><p>(<bold>A,B</bold>) CD44 expression profile in WT but not in CD44 KO hNSC was verified by (A) western blot and (B) Immunocytochemistry (scale bar 30 µm). (<bold>C,D</bold>) p-ERK western blot analysis of protein lysates from WT and CD44 KO hNSC shows that C1q-induced ERK activation is completely blocked in CD44 KO hNSC at C1q [0.1 nM] and [1 nM], and dramatically attenuated at C1q [200 nM]. p-ERK band optical intensities were normalized to β-actin within condition. Data show mean ± SEM (N = 3 biological replicates per condition) normalized to untreated controls for comparison between conditions (dashed line). Statistical analysis using one-sample t-test (NS, not significant; *p≤0.05) for comparison with control and Student’s t-test for comparison between WT and CD44 KO hNSC as indicated (*p≤0.05, **p≤0.01). (<bold>E</bold>) Transwell chemotaxis assay reveals that C1q-induced hNSC chemotaxis is completely blocked in CD44 KO hNSC at C1q [0.1 nM] and dramatically attenuated at C1q [200 nM]. Data show mean ± SEM (N = 3 biological replicates per condition) normalized to untreated controls (dashed line). Statistical analysis using one-sample t-test (NS, not significant; *p≤0.05) for comparison with control and Student’s t-test for comparison between WT and CD44 KO hNSC as indicated (*p≤0.05, **p≤0.01).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>WT and CD44 KO hNSC generation.</title><p>The human CD44 loci (gene ID: 960) was targeted using the CRISPR/Cas9 system to create genetic knockout via non-homologous end joining (NHEJ). (<bold>A</bold>) CD44 Guide RNA sequences. For maximum disruption of CD44’s ORF, two guide RNAs (gRNAs) were simultaneously introduced into hNSC with chimeric guide RNA + hspCas9 co-expression vector. (<bold>B</bold>) hspCas9 co-expression vector. (<bold>C</bold>) Snap Gene Graphics for gRNA alignment. Both gRNAs (purple) were designed to target the second exon of CD44 to generate a 47 bp deletion within exon two resulting in a frame-shift that introduces a pre-mature stop codon within a targeted exon. (<bold>D</bold>) WT and CD44 KO FACS sorting after CRISPR. Two weeks after plasmid introduction, unsorted CRISPR-modified hNSC were separated based on CD44 expression using fluorescence activated cell sorting (FACS); CD44-negative knockout cells (29.7% of the total population) were isolated based on the gating of our unstained control; CD44-positive wild-type cells (39.3% of the total population) were isolated based on the gating of our positive control, unmodified CD44-PE-stained cells. FACS-isolated CD44 WT and CD44 KO hNSC retain expression identity after multiple passages. (<bold>E</bold>) Flow citometry analysis of CD44 WT and KO hNSC. After more than a month in culture, and having undergone four passages, we re-analyzed the expression of CD44 in WT and KO cells. FACS-isolated CD44 WT hNSC retained CD44 expression; 96.3% CD44-PE positive and 1.87% CD44-PE negative. FACS-isolated KO hNSC retained a CD44-negative expression phenotype; 99.7% CD44-PE negative and 0.24% CD44-PE positive. (<bold>F</bold>) Fluorescent images of CD44 WT immediately after flow cytometry. (<bold>G</bold>) Fluorescent images of CD44 KO immediately after flow cytometry. After CD44 -PE staining, hNSC were counterstained with Hoechst to label cell nuclei and then mounted on a slide using a Cytospin 4 centrifuge (Thermo Scientific). Scale bars 30 µm. Images were taken in an inverted fluorescent microscope at 20×.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>CD44 WT and CD44 KO hNSC genotyping by sequencing.</title><p>(<bold>A</bold>) Human CD44 locus: Location of guide RNAs (gRNA) and genotyping primers. CD44-WT or CD44-KO hNSC generated by NHEJ with CRISPR/Cas9 system. Two primer sets (forward primer in green), (reverse primer in red) were used to amplify and/or sequence the region surrounding the targeted site. Graphics were produced using SnapGene software. The targeted site was then amplified using a high-fidelity polymerase and highly specific primer set (CD44_2 F/CD44_2R); this primer set was optimized to produce a single amplicon of 422 bp. This amplicon was then purified and submitted for Sanger sequencing to Retrogen Inc; each amplicon was sequenced with four different primers. The raw chromatograph data from the Sanger sequencing was then aligned with the targeted site using SnapGene software. (<bold>B</bold>) Alignment of CD44 WT sequencing results. FACS isolated CD44-positive hNSC showed no genetic changes within the targeted exon (no double peaks at any positions). (<bold>C</bold>) Alignment of CD44 KO sequencing results. FACS isolated CD44-negative hNSC contained a 47 bp deletion within exon 2 resulting in a frame-shift that introduced a premature stop codon within targeted exon; the same deletion was consistently detected in all traces. (<bold>D</bold>) Table containing all of the sequences used in producing the data of this figure.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Karyotype, stemness, proliferation capacity, and multipotency are unaltered after CRISPR Cas9 genetic deletion of CD44 in hNSC.</title><p>(<bold>A,B</bold>) CD44 WT and KO hNSC are karyotypically normal at p7. CD44 WT/KO hNSC were submitted to Cell Line Genetics, for G-banding karyotyping. (A) FACS-isolated CD44 wildtype (WT) G-banding karyotyping. (B) FACS-isolated CD44 knockout (KO) G-banding karyotyping. (<bold>C,D</bold>) CD44 WT and CD44 KO hNSC express similar levels of CD133+ cells. (C) CD44 WT and (D) CD44 KO hNSC were assessed for expression of the ‘stemness’ marker CD133. Relative to the unstained control, at passage 7, CD44 WT and CD44 KO hNSC express similar levels of CD133 as measured by flow cytometry; 96.1% and 93.5%, respectively. (<bold>E-G</bold>) CD44 WT and CD44 KO hNSC exhibit similar proliferation levels. Representative image of EdU (green) + nuclei and Hoechst counterstain (blue) of (E) CD44 WT and (F) CD44 KO hNSC. White arrows indicate examples of EdU+ nuclei, scale bars 30 µm. (<bold>G</bold>) EdU incorporation quantification at 2 d in vitro (DIV). Data shown as proportion of EdU+ cells for CD44 WT (blue column) and KO (red column), Mean + SEM. Student’s t-test, NS = not significant p=0.1126, N = 4 biological replicates. (<bold>H-S</bold>) Genetic deletion of CD44 in human NSC did not alter multipotency of hNSC but increased oligodendroglial differentiation in vitro. After 14DIV under differentiation conditions, cells were immunostained for an oligodendroglial marker (Olig2+, green). A second set of cells was double immunostained for astroglial (GFAP+, red) and neuronal (β tubulin III+, green) markers. Representative image of Olig2 immunostaining in (<bold>H</bold>) WT and (<bold>I</bold>) CD44 KO hNSC. White arrows indicate examples of Olig2+ nuclei, scale bars 30 µm. (<bold>J</bold>) Olig2+ nuclei quantification (%). Representative image of GFAP immunostaining in (<bold>K</bold>) CD44 WT and (<bold>L</bold>) CD44 KO hNSC. Pink arrows indicate examples of cytoplasmic GFAP+/β tubulin III- astroglial cells, scale bars 30 µm. (<bold>M</bold>) GFAP+/β-tubulinIII- astroglial cell quantification (%). Representative image of β-tubulinIII immunostaining in (<bold>N</bold>) CD44 WT and (O) CD44 KO hNSC. Green arrows point to examples of cytoplasmic GFAP-/β tubulinIII+ neuronal cells, scale bars 30 µm. (P) GFAP-/β tubulin III+ neuronal cell quantification (%). Representative image of GFAP and β tubulinIII double immunostaining in (Q) CD44 WT and (R) CD44 KO hNSC. White arrows point to examples of GFAP+/β tubulinIII+ undecided double positive cells, scale bars 30 µm. (<bold>S</bold>) GFAP+/β tubulin III+ double + undecided cell quantification (%). Data represent average percentage ± SEM of quantified positive cells, obtained from 10 random pictures/experiment, from N = 4 biological replicates (averaging 140 ± 60 cells/picture). Statistical analysis was performed using Student’s t-test between WT and CD44 KO hNSC; NS: not significant p≥0.2455, ****p≤0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>CD44 WT and KO mNSC cell line generation.</title><p>Mouse NSC (mNSC) from CD44 WT and KO mice were derived from single embryo cortices at E11.5–12. DNA of parent mice and each littermate embryo was extracted from tail snips and direct PCR performed for genotyping. (<bold>A</bold>) Primers used for genotyping CD44 WT, KO, and heterozygous embryos. (<bold>B</bold>) Genotyping results of WT and CD44KO parents and first-generation heterozygous CD44 +/– colonies. (<bold>C</bold>) Genotyping results of WT and CD44 KO embryos that were used to generate CD44 WT and KO mNSC lines. (<bold>D</bold>) CD44 expression in CD44 WT and CD44 KO mNSC by immunostaining verifies positive staining only in WT cells. (<bold>E</bold>) mNSC express all C1q novel candidate receptors. mRNA RT-PCR analysis in mNSC reveals the positive expression of all C1q novel signaling candidates. (<bold>F</bold>) mNSC migrate toward PMN-CM and C1q similar to hNSC in vitro. Transwell chemotaxis assay shows that PMN-CM and C1q [200 nM] but not Mφ-CM induce mNSC chemotaxis. Data normalized to untreated control (dashed line; N = 3 biological replicates per condition with technical triplicates). Statistical analysis using one-sample t-test (NS, not significant; *p≤0.05, ***p≤0.001) for comparison with control. ANOVA analysis for comparison between groups, p=0.0018. (<bold>G</bold>) CD44 WT but not KO mNSC migrate toward C1q [200 nM] similar to hNSC in vitro. Transwell chemotaxis assay shows that C1q [200 nM] induces mNSC chemotaxis only in CD44 WT cells, while KO cells are repulsed by C1q. Both effects are blocked by temperature inactivation of C1q. Data normalized to untreated control levels (dashed line; N = 3 biological replicates per condition with technical triplicates). Statistical analysis using one-sample t-test (NS, not significant; *p≤0.05, ***p≤0.001) for comparison with control, ANOVA analysis for comparison between groups, ****p≤0.0001, and Student’s t-test for comparison between WT and CD44 KO mNSC as indicated (***p≤0.001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig5-figsupp4-v2.tif"/></fig></fig-group><p>We investigated the functional effect of CD44 KO on hNSC intracellular signaling in response to C1q. CD44 KO cells did not exhibit p-ERK activation in response to C1q [0.1 nM] or C1q [1 nM] in comparison with WT cells, and exhibited a significant attenuation in response to C1q [200 nM] (<xref ref-type="fig" rid="fig5">Figure 5C,D</xref>). Based on the effect of p-ERK inhibition on hNSC migration (<xref ref-type="fig" rid="fig4">Figure 4F</xref>), we subsequently tested whether CD44 mediates C1q-induced hNSC migration in transwell assays. Baseline migration in control media was not significantly different between WT and CD44 WT and KO hNSC (Student’s t-test, p=0.1785). As shown earlier (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>) and in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>, CD44 WT hNSC exhibited concentration-dependent migration in response to C1q [0.1 nM] and [200 nM] (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). By contrast, CD44 KO hNSC did not migrate in response to C1q [0.1 nM], and migration was dramatically attenuated in response to C1q [200 nM] (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, N = 4), demonstrating that CD44 is involved in C1q-induced signaling and chemotaxis in hNSC. The lack of complete migration blockade in response to C1q [200 nM] could be related to concentration-dependent activation of ERK/MAPK pathway signaling via C1q interaction with other receptor candidates.</p><p>To validate that these results were not due to off-target effects of CRISPR-Cas9, we employed a parallel genetic approach, generating mouse NSC (mNSC) from either CD44 WT or CD44 KO littermate mouse embryos (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4A–D</xref>). We confirmed that mNSC exhibit the expression of CD44 and the other C1q signaling/receptor candidates (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4E</xref>), as well as a comparable response to complement components and the inflammatory injury microenvironment (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>), including induction of mNSC chemotaxis (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4F</xref>). These data demonstrate the conservation of this mechanism across species. The loss of CD44 protein expression in KO vs. WT mNSC was confirmed using immunocytochemistry (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4D</xref>), and transwell assays were used to verify C1q induced migration as for hNSC. Baseline migration in control media was identical between CD44 WT and KO mNSC (Student’s t-test, p=0.6150). However, while WT mNSC exhibited increased migration in response to C1q (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4F,G</xref>) similar to WT hNSC (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>, <xref ref-type="fig" rid="fig4">Figure 4E</xref>), this response was completely blocked in CD44 KO mNSC (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4G</xref>). Indeed, CD44 KO mNSC exhibited a repulsive effect in response to C1q. Temperature inactivation of human C1q abolished all responses (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4G</xref>), confirming both specificity and a requirement for functional 3D conformation of the C1q protein. In summary, these in vitro findings demonstrate that CD44 is involved in C1q-mediated signaling pathway activation and chemotaxis in mammalian NSC.</p></sec><sec id="s2-4"><title>C1q modulation of hNSC proliferation and differentiation is CD44 independent</title><p>We have previously shown that C1q alters hNSC proliferation and differentiation (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). We therefore tested whether C1q acts through CD44 to mediate these effects in addition to cell migration. We assessed cell proliferation via EdU incorporation after 2DIV in DM in the presence or absence of C1q. No difference was observed between CD44 WT and KO hNSC baseline proliferation (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3E–F</xref>, noted above), or proliferation response to C1q at any tested C1q concentration (ANOVA and Tukey post-hoc t-tests as indicated in <xref ref-type="fig" rid="fig6">Figure 6A–C</xref>; Tukey p=0.999). These data demonstrate that the effects of C1q on hNSC proliferation are CD44 independent.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>C1q modulation of hNSC proliferation and fate is CD44 independent.</title><p>(<bold>A-C</bold>) EdU incorporation analysis reveals that C1q exposure for 2DIV (0.1 nM–200 nM vs. control media, as indicated) exerts comparable effects on hNSC proliferation in CD44 WT and KO. Representative images (A, B; white arrows, scale bar 30 µm) and quantification (<bold>C</bold>) of EdU+ nuclei of CD44 WT (blue) and KO (red) hNSC. (<bold>D-O</bold>) Immunohistochemical fate analysis reveals that C1q exposure for 14DIV in DM (0.1 nM–200 nM vs. control media, as indicated) exerts comparable effects on hNSC fate in CD44 WT and KO. hNSC were immunolabeled for Olig2 (green) to identify oligodendroglial lineage cells, and doubled immunolabeled for glial fibrillary acidic protein (GFAP, red) and Tubulin βIII (TubβIII, green) to identify astroglial and neuronal lineage cells, respectively. Representative images and quantification of nuclear Olig2+ oligodendroglial cells (<bold>D-F</bold>; white arrows, scale bar 30 µm), GFAP+/TubβIII- astroglial cells (<bold>G-I</bold>; pink arrows, scale bar 30 µm), GFAP-/TubβIII+ neuronal cells (<bold>j-l</bold>, green arrows, scale bar 30 µm), and GFAP+/TubβIII+ double-positive ‘undecided’ cells (<bold>M-O</bold>, white arrows, scale bar 30 µm). Data represent average number of cells as a percentage of total nuclei ± SEM of EdU labeled or immunolabeled cells obtained from 10 random fields/experiment (N = 4 biological replicates for each label and condition; average 140 ± 60 cells/field). Statistical analysis was performed using one-way ANOVA (####p≤0.0001) followed by Tukey’s post-hoc t-tests as indicated (NS, not significant; *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001). No significant differences were observed between WT and CD44 KO hNSC in response to C1q at any tested C1q concentration (Tukey post-hoc t-tests p≥0.7891 for all comparisons).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig6-v2.tif"/></fig><p>Next, we tested the effect of C1q on the fate of CD44 WT and KO hNSC during 14DIV differentiation in DM, analyzing nuclear Olig2, GFAP, and βIII-tubulin immunolabeling. When exposed to C1q at [0.1 nM] or [1.0 nM], WT hNSC exhibited a significant increase in Olig2+ cells vs. control (<xref ref-type="fig" rid="fig6">Figure 6D–F</xref>; C1q [0.1 nM] 29% vs. control 21%, Tukey p=0.022; C1q [1.0 nM] 28% vs. control 21%, Tukey p=0.048), which was attenuated in CD44 KO hNSC (<xref ref-type="fig" rid="fig5">Figure 5E–F</xref>; C1q [0.1 nM] 29% vs. control 30%, Tukey p=0.999; C1q [1.0 nM] 31% vs. control 30%, Tukey p=0.999). This result is likely to reflect an indirect effect of increased Olig2+ cell number observed under baseline differentiation conditions for CD44 KO vs. WT hNSC (30% vs. 21%; <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3G,H</xref>, noted above), creating a ceiling effect for C1q-driven increases in Olig2+ cell number. Byn contrast, when exposed to C1q [200 nM] both WT and CD44 KO hNSC exhibited a significant and equivalent decrease in Olig2+ cells (<xref ref-type="fig" rid="fig6">Figure 6F</xref>; in CD44 WT: C1q [200 nM] vs control 10% vs. 21%, Tukey p&lt;0.0001; KO C1q [200 nM] vs control 14% vs. 30%, Tukey p&lt;0.0001). CD44 WT and KO hNSC exhibited comparable concentration-dependent responses to C1q in astroglial (GFAP+/βIII-tubulin-, <xref ref-type="fig" rid="fig6">Figure 6G–I</xref>), neuronal (GFAP-/βIII-tubulin+, <xref ref-type="fig" rid="fig6">Figure 6J–L</xref>), and undecided (GFAP+/βIII-tubulin+ cells, <xref ref-type="fig" rid="fig6">Figure 6M–O</xref>) cell fate, with no significant differences observed between CD44 WT and KO hNSC in response to C1q at any tested C1q concentration (ANOVA and Tukey post-hoc t-tests as indicated in <xref ref-type="fig" rid="fig6">Figure 6</xref>). In accordance with this observation and as noted above, no significant differences were observed between CD44 WT and CD44 KO hNSC baseline astroglial or neuronal fate (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3K–S</xref>). In all, these data are consistent with our previous report of a dose dependent effect of C1q on hNSC differentiation (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>), and demonstrate that the effects of C1q on astroglial and neuronal fate are independent of CD44. These data suggest that C1q functions through one or more of the other receptor candidates identified and their associated signaling pathways (e.g., GPCR signaling) to regulate hNSC proliferation and differentiation/fate.</p><p>CD44 KO decreases hNSC localization at the SCI epicenter, modulating astroglial fate and rescuing the capacity of hNSC to promote locomotor recovery after transplantation into the acute SCI microenvironment.</p><p>We have previously shown that the time of hNSC transplantation into the parenchyma adjacent to the SCI epicenter is a key variable for the in vivo fate and migration profile of engrafted donor human cells. Delayed hNSC transplantation (9–30/60 d post-SCI) results in extensive donor human cell migration away from the SCI epicenter, toward the distal rostral and caudal spinal cord, and predominant oligodendroglial differentiation (<xref ref-type="bibr" rid="bib72">Yonemasu et al., 1978</xref>; <xref ref-type="bibr" rid="bib58">Salazar et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Hooshmand et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Cummings et al., 2006</xref>). Conversely, acute hNSC transplantation (0 d post-SCI) results in increased donor human cell migration toward the SCI epicenter and a pronounced shift toward astroglial fate in the donor human cell population that engrafts adjacent to it (<xref ref-type="bibr" rid="bib42">Nguyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). Moreover, while delayed hNSC transplantation leads to locomotor recovery, acute transplantation does not. These effects can be rescued by specific systemic immunodepletion of the PMN cell population with anti-Ly6G antibody (<xref ref-type="bibr" rid="bib42">Nguyen et al., 2017</xref>), as well as by C1q+C3a blockade via epicenter administration of neutralizing antibodies (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). Based on these data and the identification of a novel role for CD44 expressed by hNSC in C1q-induced chemotaxis, we hypothesized that: 1) CD44 KO hNSC would exhibit reduced migration to the SCI epicenter after acute transplantation; 2) CD44 KO hNSC would exhibit reduced astroglial differentiation at the SCI epicenter after acute transplantation; and 3) CD44 KO hNSC would promote functional locomotor recovery after acute transplantation, while CD44 WT cells would not.</p><p>We first sought to demonstrate that there is a spatial and temporal C1q gradient, with highest levels in the injury epicenter and a peak in the acute period that could drive donor hNSC migration via C1q-CD44 interaction. We analyzed C1q protein in Rag one mice that received a T9 laminectomy alone (sham) or a T9 laminectomy plus a 50 kD contusion SCI, collecting spinal cord tissue in rostral, epicenter and caudal 3 mm segments (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>) at 3 hr, 24 hr or 9 d post-injury (pi). Using SDS-PAGE and western blot analysis, we verified that C1q protein is significantly increased at acute time points (3-24hpi) in the injury epicenter (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–C</xref>). Plasma C1q circulates in the C1 complex, which is composed of C1q, C1r, and C1s. Also, a multitude of cells in the CNS can synthesize C1q, including PMN and Mφ, which do so both in vitro and in vivo after SCI (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). Detection of C1q by western blot could thus indicate the presence of either C1q as a single protein or C1 complex. Consistent with this suggestion, microarray gene expression data overlapping these regions and time points shows a parallel increase in local C1q mRNA at the injury epicenter that is not accompanied by C1s mRNA (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D,E</xref>; <xref ref-type="bibr" rid="bib2">Aimone et al., 2004</xref>), suggesting that locally synthesized C1q would be bioavailable for interaction as a single molecule, separate from C1 complex. Together, these data demonstrate that C1q is present in the SCI microenvironment acutely at the lesion epicenter, and supports that C1q would be available to interact with CD44 and drive hNSC migration to the SCI epicenter after acute transplantation of donor hNSC.</p><p>To test if CD44 mediates hNSC recruitment toward the SCI epicenter after acute transplantation, 75,000 CD44 WT or KO hNSC were transplanted bilaterally into four sites (250 nL/site) in the intact parenchyma, two sites 1 mm rostral and two sites 1 mm caudal to the SCI epicenter, immediately after a moderate (50 kD) T9 contusion injury (<xref ref-type="bibr" rid="bib42">Nguyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). To enable adequate xenograft survival for analysis of survival and migration, we employed immunodeficient Rag-1 mice; while the adaptive T and B cell response is absent in these animals, innate immune responses, including PMN infiltration, macrophage/monocyte infiltration, and early complement molecules are retained. Donor CD44 WT and CD44 KO hNSC engraftment were observed in 100% of transplanted animals (N = 10/group). A subset of six animals was randomly selected from each group for immunohistology and unbiased stereological analysis (MBF StereoInvestigator). Fibronectin+ lesion volume was quantified using the Cavalieri probe. Similarly, the number of human-specific cytoplasmic marker (STEM121) and human-specific astrocyte marker (STEM123) positive hNSC was quantified using the optical fractionator probe. Additionally, we have previously reported that, while hNSC in this acute transplantation paradigm do not invade the Fibronectin+ injury site per se, the robust magnitude of hNSC localized to the spared parenchyma adjacent to the SCI epicenter leads to undersampling in stereology; accordingly, we also analyzed human donor cell localization in this region using volumetric sampling with the Cavalieri probe (clustering) (<xref ref-type="bibr" rid="bib42">Nguyen et al., 2017</xref>). All histological analyses were performed by observers blinded to the study groups 16 weeks post-transplant (WPT).</p><p>No differences in fibronectin+ lesion volume (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A,B</xref>), or in the number of surviving engrafted donor human cells (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2C,D</xref>; hNSC STEM121+ cells in brown) were observed in mice receiving CD44 WT vs. KO hNSC. However, consistent with our hypotheses, mice transplanted with CD44 KO hNSC exhibited a significant reduction in total STEM121+ donor cells adjacent to the SCI epicenter (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>). Similarly, mice transplanted with CD44 KO hNSC exhibited a significant reduction in hNSC derived STEM123+ astrocyte clustering (h-astrocytes, <xref ref-type="fig" rid="fig7">Figure 7D–H</xref>) adjacent to the SCI epicenter and STEM123+ h-astrocytes in the spared parenchyma within 1 mm rostral-caudal to the SCI epicenter (<xref ref-type="fig" rid="fig7">Figure 7I</xref>). These data suggest that CD44 KO decreased the migration of transplanted hNSC toward the SCI epicenter, which was associated with decreased astroglial fate, and that this effect did not result from alterations in lesion volume or total donor cell engraftment and survival. Further, analysis of locomotor recovery on the horizontal ladder beam task, a sensitive task for animals exhibiting frequent stepping, showed that mice receiving CD44 KO hNSC made significantly fewer errors vs. mice receiving vehicle controls (<xref ref-type="fig" rid="fig7">Figure 7J</xref>), while no improvements were observed after transplantation of WT hNSC. Taken together, these data demonstrate that CD44 modulates hNSC migration and distribution in the in vivo acute microenvironment after SCI, affecting both lineage selection and the potential to yield locomotor recovery. While identification of C1q as a novel CD44 ligand suggests a novel mechanism by which hNSC CD44 expression may regulate the behavior of these cells in vivo, this experiment cannot rule out the potential contribution of other CD44 ligands in the SCI microenvironment.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>CD44 KO decreases hNSC localization at the SCI epicenter, modulating astroglial fate and rescuing the capacity of hNSC to promote locomotor recovery after transplantation into the acute SCI microenvironment.</title><p>All histological data obtained 16 weeks post-transplant (WPT). (<bold>A,B</bold>) Representative images of transverse spinal cord sections corresponding to the injury epicenter area immunostained for the human-specific cell marker STEM121 (brown; scale bars, 250 µm) and hematoxylin nuclear counterstain (purple) on spinal cords from mice transplanted with WT (blue) or CD44 KO (red) hNSC. (<bold>C</bold>) Stereological analysis of STEM121+ human cell clustering using Cavalieri sampling demonstrates a decrease in CD44 KO vs. WT human cells adjacent to the SCI epicenter. Data show mean ± SEM (N = 5–6 mice randomly selected for histology/group). Statistical analysis using Student’s t-test as indicated (**p≤0.01). (<bold>D,E</bold>) Representative image of transverse spinal cord section corresponding to the injury epicenter area immunostained for the human astrocyte specific marker STEM123 (brown; scale bars, 250 µm) and hematoxylin nuclear counterstain (purple) in spinal cords from mice transplanted with (<bold>D</bold>) WT or (<bold>E</bold>) CD44 KO hNSC. (<bold>F</bold>) Stereological analysis of STEM123+ h-astrocyte clustering using Cavalieri sampling demonstrates a decrease in CD44 KO vs. WT h-astrocytes adjacent to the SCI epicenter. Data show mean ± SEM (N = 5–6 mice randomly selected for histology/group). Statistical analysis using Student’s t-test as indicated (*p≤0.05). (<bold>G,H</bold>) Representative three-dimensional reconstructions generated by stereological quantification of the lesion Fibronectin+ area (orange volume), STEM123+ clusters (purple volume), and individual STEM123+ cells (light purple dots) from mice transplanted with CD44 WT or KO hNSC. (<bold>I</bold>) Stereological analysis of STEM123+ h-Astrocyte number in the spared tissue adjacent to the SCI epicenter demonstrates a decrease in CD44 KO vs. WT localized in these regions. Data show mean ± SEM (N = 5–6 mice randomly selected for histology/group). Statistical analysis using Student’s t-test as indicated (*p≤0.05). (<bold>J</bold>) CD44 KO in hNSC rescues the capacity of acutely transplanted hNSC to promote locomotor recovery. Mice transplanted acutely with CD44 KO but not WT hNSC made significantly fewer errors on the horizontal ladder beam locomotor task in comparison with vehicle-treated mice 16 WPT. Data shown as number of errors normalized to vehicle-treated mice (dashed line; N = 8–10 mice/group). Statistical analysis using one-sample t-test (NS, not significant, ***p≤0.0005) for comparison with control vehicle-treated mice and via one-way ANOVA (#) p&lt;0.05 followed by Tukey’s post-hoc t-test as indicated (NS, not significant; #p≤0.05) for comparison between conditions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>C1q protein increases in the epicenter acutely after SCI.</title><p>(<bold>A</bold>) Schematic illustrating the spinal cord sections utilized to determine C1q protein levels following 50 KDa spinal cord contusion injury or laminectomy control. (<bold>B</bold>) C1q Western blot on 3 mm rostral, epicenter, and caudal sections after laminectomy or SCI at 3 hr, 24 hr, and 9 d post-SCI reveals significantly increased C1q protein levels in the epicenter and at acute (3 hr and 24 hr) time points. (<bold>C</bold>) C1q band intensities were normalized to β-actin. Data show mean ± SEM (N = 4 mice/time point) for quantified C1q optical intensities. Statistical analysis of C1q levels was significant using one-way ANOVA at ****p≤0.0001, followed by Tukey’s post-hoc t-test as indicated (NS, not significant; *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001). (<bold>D,E</bold>) mRNA expression analysis reveals a parallel increase in local C1q mRNA synthesis at the injury epicenter that is not accompanied by C1s mRNA. (<bold>D</bold>) C1q and (<bold>E</bold>) C1s gene expression changes after spinal cord injury were obtained by data analysis of our published microarray data following contusive injury of the adult rat spinal cord. Differential gene expression was examined spatially, using tissue samples from the epicenter of the injury as well as 1 cm rostral and 1 cm caudal to the epicenter, and temporally, at 3 hr, 24 hr, 7 d, and 35 d post-injury, as described in <xref ref-type="bibr" rid="bib2">Aimone et al., 2004</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>CD44 KO hNSC does not alter lesion volume or total hNSC engraftment after transplantation in the SCI acute microenvironment.</title><p>Histological analysis at 16 WPT. (<bold>A</bold>) Representative image of a transverse spinal cord section immunostained for fibronectin-at the SCI epicenter (FN+, blue; scale bar = 150 μm) and STEM123+ human astrocytes (brown). Sections were counterstained for nuclei using hematoxylin (purple). (<bold>B</bold>) Quantification of host lesion volume by unbiased stereology using the Cavalieri probe in SCI mice that received WT (blue squares) or KO (red circles) hNSC. Comparisons between groups were analyzed using Student’s t-test (NS, p=0.589). (<bold>C</bold>) Immunohistochemistry for the human-specific cytoplasmic marker STEM121 (brown; scale bar = 25 μm) Sections were counterstained for nuclei using hematoxylin (purple); arrowheads indicate STEM121+ cells with hematoxylin + nuclei as quantified. (<bold>D</bold>) Quantification of the total number of hNSC by unbiased stereology using the optical fractionator probe in mice that received CD44 WT (blue squares) vs. CD44 KO (red circles) hNSC. Comparisons between groups were conducted using Student’s t-test (NS, p=0.338). Dashed line indicates the transplantation dose of 75,000 cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig7-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Epicenter C1q neutralization is comparable to CD44 KO in modulating hNSC behavior and capacity for repair after acute transplantation</title><p>CD44 has multiple ligands, including hyaluronic acid and components of the extracellular matrix (laminin, collagen , osteopontin; <xref ref-type="bibr" rid="bib55">Ponta et al., 2003</xref>; <xref ref-type="bibr" rid="bib70">Weber et al., 1996</xref>) many of which are altered in the injured spinal cord (<xref ref-type="bibr" rid="bib64">Struve et al., 2005</xref>; <xref ref-type="bibr" rid="bib23">Hashimoto et al., 2003</xref>; <xref ref-type="bibr" rid="bib9">Bernstein et al., 1985</xref>). If C1q interaction is necessary for the role of CD44 in hNSC migration and capacity for repair, then we reasoned that C1q depletion at the SCI epicenter would be sufficient to reproduce the effect of genetic CD44 KO on transplanted hNSC. We employed a previously published approach and reagents (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>), transplanting WT hNSC into the rostral and caudal spared parenchyma immediately after T9 moderate contusion SCI, as described earlier. Acute hNSC transplantation was followed immediately by a single epicenter injection of either vehicle (hNSC + vehicle) or C1q neutralizing antibody (hNSC + C1qNAb). We have previously shown that there are no differences between NAb treatment, IgG control, and vehicle treatment with regard to hNSC cell engraftment and lesion volume (one-way ANOVA, p=0.493) (<xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). Histological quantification was performed by blinded unbiased stereological analysis as described earlier, and the effect of C1qNAb administration on lesion volume as well as hNSC engraftment and h-astrocyte localization analyzed at 12 WPT. As for CD44 WT vs. KO hNSC transplantation, no differences in fibronectin+ lesion volume (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A,B</xref>) or total donor STEM 121+ cell hNSC engraftment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C,D</xref>) were observed in C1qNAb treated vs. vehicle-treated control mice. Similarly, consistent with the effect of CD44 KO, the number of hNSC that had committed to an astroglial fate adjacent to the SCI epicenter was significantly decreased in C1qNAb treated vs. vehicle-treated control mice at 12WPT (<xref ref-type="fig" rid="fig8">Figure 8A–C</xref>). Further, C1q NAb treatment also rescued the capacity of donor hNSC to promote recovery of locomotor function. While no differences in ladder beam errors were observed at 12 WPT (one-way ANOVA, p=0.4743; data not shown), the more sensitive CatWalk kinematic gait analysis showed significant improvement in mice receiving hNSC + C1qNAb for hindlimb duty cycle, hindpaw stand time, and support three paws, indicating increased weight- bearing vs. vehicle in a one-sample t-test (<xref ref-type="fig" rid="fig8">Figure 8D–F</xref>). Taken together, these data suggest that C1q blockade results in modulation of hNSC behavior and the potential of hNSC for repair in a manner that is consistent with CD44 KO in these cells.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Epicenter C1q neutralization is similar to CD44 KO in modulating hNSC behavior and capacity for repair after acute transplantation.</title><p>All histological data are from animals sacrificed at 12 weeks post-transplant (WPT). (<bold>A,B</bold>) Representative images of transverse spinal cord sections corresponding to the injury epicenter area immunostained for the h-Astrocyte STEM123 marker (brown, hematoxylin nuclear counterstain in purple; scale bars, 250 µm). (<bold>A</bold>) In the absence of C1qNAb, a dense plexus of h-Astrocytes is present near the injury epicenter. (<bold>B</bold>) A single epicenter injection of C1qNAb in acute SCI microenvironment dramatically decreases the proportion of h-astrocyte at the SCI epicenter. (<bold>C</bold>) Stereological analysis of STEM123+ h-Astrocytes in the spared tissue adjacent to the SCI epicenter, as well as in 1 mm regions rostral and caudal at 12WPT. Data show mean ± SEM (N = 6 mice per group). Statistical analysis using Student’s t-test for comparison between vehicle + hNSC treated mice and C1qNAb + hNSC treated mice as indicated (*p&lt;0.0261). (<bold>D-F</bold>) Catwalk kinematic gait analysis at 12 WPT shows that mice receiving C1qNAb + hNSC, but not vehicle + hNSC improves locomotor function in Catwalk kinematic testing vs. mice receiving only vehicle + vehicle. (<bold>G</bold>) Hindpaw duty cycle (% mean). (<bold>H</bold>) Catwalk Hindpaw stand mean (s). (<bold>I</bold>) Support three paws (%), indicating increased weight bearing. Data show mean ± SEM normalized to vehicle+vehicle-treated mice (as explained in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> only a subset of animals reached sufficient stepping parameters in this experiment to perform on CatWalk N = 3–5 mice per group as shown by individual points in graphs). Statistical analysis using Student’s t-test for comparison between vehicle + hNSC treated mice and C1qNAb + hNSC treated mice as indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>C1q epicenter blockade does not alter lesion volume or hNSC engraftment after transplantation.</title><p>Histological analysis at 12 WPT. (<bold>A</bold>) Representative image of transverse spinal cord section immunostained for fibronectin at the SCI epicenter (brown; scale bar = 150 μm). (<bold>B</bold>) Quantification of host lesion volume by unbiased stereology using the Cavalieri probe in SCI mice that received vehicle + vehicle (green triangles), vehicle + hNSC (blue squares), or C1qNAb + hNSC (red circles). Mean ± SEM (N = 5–7). Comparisons between groups were conducted using one-way ANOVA (NS, p=0.6073). (<bold>C</bold>) Immunohistochemistry for the human-specific cytoplasmic marker STEM121 (brown; scale bar = 25 μm). Sections were counterstained for nuclei using methyl green; arrowheads indicate SC121+ cells with methyl green+ nuclei as quantified. (<bold>D</bold>) Quantification of the total number of hNSC by unbiased stereology using the optical fractionator probe in mice that received vehicle + hNSC (blue squares) vs. C1qNAb (red circles). Comparisons between groups were conducted using Student’s t-test (NS, p=0.4276).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-fig8-figsupp1-v2.tif"/></fig></fig-group><p>Collectively, these data identify a novel ligand-receptor relationship for C1q and CD44, a novel role for CD44 in donor hNSC behavior, and a link between C1q-CD44 regulated donor hNSC distribution, fate and recovery of function after transplantation. Importantly, these findings suggest the potential for the optimization of cell therapies by manipulating hNSC responses to the host inflammatory microenvironment for CNS injuries and/or diseases.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>C1q first appeared in the phylogenetic scale about 450 million years ago, and multiple studies suggest that this protein has evolved roles that are not restricted its functions in the innate immune response, particularly in the CNS (<xref ref-type="bibr" rid="bib50">Peterson and Anderson, 2014</xref>). Here, we hypothesized that C1q signals to NSC as a functional ligand via receptor-mediated interactions to modulate stem cell behavior. Consistent with this hypothesis, we demonstrate the first evidence for a receptor-mediated signaling role for complement C1q in the CNS, modulating NSC migration, proliferation, and lineage commitment. Moreover, using an unbiased forward screen, we define and validate five cell surface signaling/receptor candidate proteins, all of which represent novel C1q binding partners. The novelty of this technique allowed us to identify cell surface binding partners for C1q while maintaining the 3D structure of the receptor and the ligand on the cell surface of live hNSC, and validated these biologically-relevant interactions with an optimized proximity ligation assay.</p><p>The cell surface C1q signaling/receptor proteins identified, CD44, GPR62, BAI1, c-MET, and ADCY5 are all of particular interest in the CNS. CD44 is a multi-ligand, multifunctional transmembrane glycoprotein involved in cell-cell and cell-matrix interactions, cell adhesion, migration and proliferation. CD44 is a receptor for hyaluronic acid (HA), but also interacts with other extracellular matrix ligands including osteopontin, laminin, and matrix metalloproteinases (<xref ref-type="bibr" rid="bib55">Ponta et al., 2003</xref>; <xref ref-type="bibr" rid="bib70">Weber et al., 1996</xref>). This protein participates in a wide variety of cellular functions mediated by alternative splice variations between CD44 isoforms, which confer ligand specificity (<xref ref-type="bibr" rid="bib70">Weber et al., 1996</xref>). CD44 has been linked to intracellular MAPK/ERK and PI3K/Akt signaling (<xref ref-type="bibr" rid="bib24">Herishanu et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Zhang et al., 2010</xref>), but it can also control cellular signaling through interactions with other cell surface receptors, e.g., receptor tyrosine kinases (RTKs), e.g., c-Met (also identified in our forward screen), G-protein coupled receptors like CXCR4, and Wnt-induced beta-catenin (<xref ref-type="bibr" rid="bib60">Schmitt et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Orian-Rousseau and Schmitt, 2015</xref>), which requires LRP6. High expression of CD44 has been linked to commitment as an astroglial progenitor (<xref ref-type="bibr" rid="bib61">Shaltouki et al., 2013</xref>), and CD44 is highly upregulated in adult reactive astrocytes, suggesting a role in reactive astrogliosis (<xref ref-type="bibr" rid="bib73">Zamanian et al., 2012</xref>). Oligoprogenitors/immature oligodendrocytes also express CD44 (<xref ref-type="bibr" rid="bib73">Zamanian et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Naruse et al., 2013</xref>). Transgenic mice overexpressing CD44 exhibit decreased oligodendrocyte maturation (<xref ref-type="bibr" rid="bib35">Liu et al., 2004</xref>), and CD44 is required for oligoprogenitor migration after CNS transplantation (<xref ref-type="bibr" rid="bib51">Piao et al., 2013</xref>). Critically, NSC also express CD44, as we show in fetal human brain under results, and CD44 mediates transendothelial migration of neural progenitor cells (<xref ref-type="bibr" rid="bib14">Deboux et al., 2013</xref>; <xref ref-type="bibr" rid="bib57">Rampon et al., 2008</xref>). Interestingly, CD44-HA interaction has been recently implicated in hippocampal neurogenesis, as a negative regulator of adult neural progenitor proliferation (<xref ref-type="bibr" rid="bib66">Su et al., 2017</xref>).</p><p>Consistent with reported roles for CD44 on p-ERK signaling and cell migration in different cell types, in this study, we identified a novel ligand for CD44, C1q, and show that C1q-CD44 signaling specifically modulates ERK signaling and chemotaxis in hNSC in vitro. However, multiple of the C1q receptor candidates identified may signal in part via the ERK/MAPK pathway, and receptor activation is likely to be concentration-dependent, resulting in dramatic attenuation but not complete blockade of ERK signaling and migration for high C1q concentrations (C1q [200 nM]). Moreover, our data suggest that other signaling pathways (e.g., GPCR signaling for C1q modulation of hNSC proliferation) and candidate receptors may mediate different aspects of hNSC regulation by C1q. Concurrent activation of multiple signaling pathways, with specificity conferred by time, expression, and concentration, may also be biologically important.</p><p>In addition to CD44, we identified GPR62, BAI1, c-Met, and ADCY5 as hNSC cell surface interaction partners. GPR62 is an orphan, G-protein-coupled receptor (GPCR) that was identified based on a forward screen of novel GPCRs specific to the CNS and exhibits strong expression in essentially all areas of the brain (<xref ref-type="bibr" rid="bib33">Lee et al., 2001</xref>). RNAseq data analysis on purified CNS cell types from adult brain indicate that GPR62 is highly expressed in mature oligodendrocytes (<xref ref-type="bibr" rid="bib76">Zhang et al., 2014</xref>), consistent with our results from fetal brain single-cell RNA seq data analysis. GPR62 has not previously been investigated in the context of neural stem cell biology or immune interactions (<xref ref-type="bibr" rid="bib30">Khan and He, 2017</xref>). Brain-specific angiogenesis inhibitor 1 (BAI1) is part of a small subfamily of adhesion GPCRs that includes its close homologs, BAI2 and BAI3, which are developmentally regulated and highly expressed in the CNS in both fetal and adult tissue. BAI1 and BAI3 were orphan GPCRs. However, phosphatidyl serine is now known to interact with BAI1 to mediate phagocytic clearance of apoptotic cells (<xref ref-type="bibr" rid="bib5">Barth et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Park et al., 2007</xref>). Additionally, BAI1 KO mice exhibit abnormal synaptic plasticity (<xref ref-type="bibr" rid="bib77">Zhu et al., 2015</xref>) and deficits in hippocampal-dependent learning and memory, although normal synaptic arborization is maintained (<xref ref-type="bibr" rid="bib77">Zhu et al., 2015</xref>). Interestingly, C1q-like molecules induce signal transduction through the TSR region of BAI3 (<xref ref-type="bibr" rid="bib10">Bolliger et al., 2011</xref>). These data combined with the conserved homology of the TSRs across the BAI GPCR sub-family amplify interest in our preliminary identification of C1q as a BAI1 ligand. Critically, our data suggest that some C1q effects on hNSC are dependent on GPCR signaling, accordingly, future studies will investigate if GPR62 or BAI1 are involved in these observations. c-Met is an RTK, for which, hepatocyte growth factor (HGF) was the only known ligand. c-Met is expressed by cells of epithelial origin; however, in addition to the liver, c-Met expression is observed in cells of the cerebral cortex and choroid plexus (Allen brain atlas). Deregulation of c-Met expression in the adult is associated with malignancy, including cancers of the liver and brain, suggesting a role for c-Met in cell proliferation and expansion. HGF has been shown to drive NSC/progenitor cell migration via c-Met induced activation of PI3k/Akt in vitro (<xref ref-type="bibr" rid="bib32">Lan et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Fang and Lee, 2014</xref>). Further, HGF has been shown to act as both a proliferative factor and chemoattractant for subventricular zone NSC/progenitor cells (<xref ref-type="bibr" rid="bib43">Nicoleau et al., 2009</xref>; <xref ref-type="bibr" rid="bib69">Wang et al., 2011</xref>), an activity neutralized by both function blocking c-Met antibodies and expression of a dominant negative c-Met receptor (<xref ref-type="bibr" rid="bib69">Wang et al., 2011</xref>). HGF-Met signaling in these studies also played a role in the maintenance of NSC/progenitors in an undifferentiated state; reduction in this signaling axis enhanced the generation of neurons by 7-fold. In parallel, HGF-c-MET signaling has been shown to increase the generation of oligoprogenitors/oligodendrocytes from embryonic stem cells (<xref ref-type="bibr" rid="bib27">Hu et al., 2009</xref>). ADCY5 belongs to the family of membrane-bound adenylate cyclases (AC), ADCY1-9. membrane-bound AC activity controls the cellular levels and subcellular localization of cAMP, and ADCY5/cAMP have been shown to regulate many physiological and pathophysiological processes through the modulation of downstream effectors, e.g., cAMP-dependent protein kinase A (PKA) (<xref ref-type="bibr" rid="bib59">Sassone-Corsi, 2012</xref>), PI3K/Akt (<xref ref-type="bibr" rid="bib15">del Puerto et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Okumura et al., 2007</xref>), and ERK (<xref ref-type="bibr" rid="bib71">Yan et al., 2007</xref>). Further studies will be necessary to determine the biological functionalities of these other novel ligand-receptor interactions.</p><p>In sum, this study identifies both novel functions for C1q as a single molecule in the CNS and a mechanism by which this protein directly modulates NSC through the identification of a novel C1q receptor, CD44. Moreover, in vivo genetic deletion of CD44 in hNSC restored the capacity of hNSC to drive locomotor recovery after acute SCI transplantation, expanding the therapeutic window to the acute injury microenvironment. Finally, these data broaden the potential biological role for inflammatory proteins and cells in the immune microenvironment to include a multitude of conditions in which complement and in particular C1q is upregulated in the context of the developing, aged, diseased, or injured CNS. Thus, understanding the molecular interplay and communication between neuroinflammatory molecules and NSC may be critical for predicting the effects of local cues on endogenous or donor cell properties. In all, these data support the potential for clinical application of strategies to target receptor candidates on transplanted cells rather than agents from the inflammatory microenvironment to enhance the repair or restoration of function by donor cells.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Strain, strain background</td><td valign="top">Rag1 mice</td><td valign="top">JAXmice</td><td valign="top">002216 - B6.129S7-Rag1 &lt; tm1Mom&gt;/J</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background</td><td valign="top">NODSCID mice</td><td valign="top">JAXmice</td><td valign="top">001303 - NOD.Cg-Prkdc&lt;scid &gt; /J</td><td valign="top"/></tr><tr><td valign="top">Cell line</td><td valign="top">Multipotent human CNS-derived stem cells</td><td valign="top"><xref ref-type="bibr" rid="bib68">Uchida et al., 2000</xref></td><td valign="top">Stem cells inc 2491.2</td><td valign="top">Human Neural stem cells</td></tr><tr><td valign="top">Cell line</td><td valign="top">Human Neural stem cells</td><td valign="top">This paper and Piltti et al., in preparation</td><td valign="top">UCI161.1</td><td valign="top">Human Neural stem cells (UCI) correspondence to <ext-link ext-link-type="uri" xlink:href="http://www.immunology.uci.edu/profiles/anderson-aileen.asp">aja@uci.edu</ext-link></td></tr><tr><td valign="top">Transfected construct</td><td valign="top">Chimeric gRNA +hspCAS9 co-expression Vector</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.appliedstemcell.com/">https://www.appliedstemcell.com/</ext-link></td><td valign="top">Custom made</td><td valign="top">Guide RNA sequences in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref></td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-STEM121 <break/>(mouse monoclonal)</td><td valign="top">TAKARA</td><td valign="top">Cat# Y40410 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2801314">AB_2801314</ext-link></td><td valign="top">IF(1:3000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-STEM123 <break/>(mouse monoclonal)</td><td valign="top">TAKARA</td><td valign="top">Cat# Y40420 <break/>Antibody ID:<ext-link ext-link-type="uri" xlink:href="http://antibodyregistry.org/AB_2833249">AB_2833249</ext-link></td><td valign="top">IF(1:3000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Fibronectin <break/>(rabbit)</td><td valign="top">Sigma Aldrich</td><td valign="top">Cat# F3648 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_476976">AB_476976</ext-link></td><td valign="top">IF(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-C1q <break/>(mouse monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat#: ab71940 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10711046">AB_10711046</ext-link></td><td valign="top">WB (1:200) <break/>Far-WB (1:50) <break/>PLA (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-pERK <break/>(rabbit)</td><td valign="top">Cell Signaling</td><td valign="top">Cat#: 4370 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10693765">AB_10693765</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-pAkt <break/>(rabbit)</td><td valign="top">Cell Signaling</td><td valign="top">Cat#: 9916 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10693765">AB_10693765</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-CD44 <break/>(rabbit monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat#: ab51037 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_868936">AB_868936</ext-link></td><td valign="top">WB (1:1000) <break/>ICC (1:500) <break/>PLA (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-CD44 <break/>(rabbit)</td><td valign="top">Abcam</td><td valign="top">Cat#: ab189524 <break/></td><td valign="top">ICC (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-c-MET <break/>(rabbit monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat#: ab51067 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_880695">AB_880695</ext-link></td><td valign="top">PLA (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-BAI-1 <break/>(rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat#: ab135907 <break/></td><td valign="top">PLA (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GPR62 <break/>(rabbit polyclonal)</td><td valign="top">Thermo <break/>Fisher</td><td valign="top">Cat#: PA5-33745 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2551116">AB_2551116</ext-link></td><td valign="top">PLA (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-ADCY5 <break/>(rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat#: ab66037 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1140781">AB_1140781</ext-link></td><td valign="top">PLA (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Olig2 <break/>(rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat#: ab136253 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2810961">AB_2810961</ext-link></td><td valign="top">ICC (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Tubulin βIII <break/>(mouse monoclonal)</td><td valign="top">Biolegend</td><td valign="top">Cat#: MMS-435P RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2313773">AB_2313773</ext-link></td><td valign="top">ICC (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">GFAP <break/>(rabbit polyclonal)</td><td valign="top">Dako</td><td valign="top">Cat#: Z 0334 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10013382">AB_10013382</ext-link></td><td valign="top">ICC (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti CD44 -PE</td><td valign="top">Miltenyi</td><td valign="top">Cat#:130-110-293 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2658165">AB_2658165</ext-link></td><td valign="top">FACS (1:11)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti CD133-FITC</td><td valign="top">Miltenyi</td><td valign="top">Cat#:130-113-673 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2726215">AB_2726215</ext-link></td><td valign="top">FACS (1:11)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-C1qNAb (Goat-anti human)</td><td valign="top">Quidel</td><td valign="top">Cat#:A031</td><td valign="top">C1q neutralization in vivo [100 µg/mL] 2 µL injection</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Primers different mRNAs</td><td valign="top">This paper</td><td valign="top">NA</td><td valign="top"><xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref></td></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Purified human C1q</td><td valign="top">My <break/>Biosource</td><td valign="top">Cat. #: MBS143105</td><td valign="top">[0.1nM = 28 ng/mL] <break/>[1nM = 400 ng/mL] <break/>[200nM = 80µg/mL]</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">PD98059 (pERK MAPK inhibitor)</td><td valign="top">GIBCO Life Technologies</td><td valign="top">Cat. #: PHZ1164</td><td valign="top">10 µM dissolved in DMSO</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">SB203580 (p38 MAPK inhibitor)</td><td valign="top">GIBCO Life Technologies</td><td valign="top">Cat. #: PHZ1253</td><td valign="top">10 µM dissolved in DMSO</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Pertussis Toxin (GPCR inhibitor)</td><td valign="top">GIBCO Life Technologies</td><td valign="top">Cat. #: PHZ1174</td><td valign="top">10 µg/mL</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DMSO</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat. #: D26650</td><td valign="top">1:1000</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">PathScan Intracellular signaling array kit</td><td valign="top">Cell Signaling</td><td valign="top">Cat. #7744</td><td valign="top">Phosphoarray <break/>Cell signalling</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Pierce Pull-Down biotinylated protein-protein interaction kit;</td><td valign="top">Thermo</td><td valign="top">Cat. #21115</td><td valign="top">Protein pulldown</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">RNeasy Mini Kit</td><td valign="top">Qiagen</td><td valign="top">Cat No./ID: 74104</td><td valign="top">RNA extraction</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DNA-free DNase I (Ambion)</td><td valign="top">Thermo Fisher</td><td valign="top">Cat. # AM2224</td><td valign="top">DNA elimination</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">High Capacity cDNA Reverse Transcription Kit</td><td valign="top">ABI Life Technologies</td><td valign="top">Cat. # 4368814</td><td valign="top">Retrotranscription</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Duolink in situ Red starter kit Mouse/Rabbit</td><td valign="top">Sigma</td><td valign="top">Cat. # DUO92101</td><td valign="top">Proximity Ligation Assay (PLA)</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">QCM Chemotaxis Cell Migration Assay, 96-well</td><td valign="top">Millipore/ <break/>Chemicon</td><td valign="top">Cat. # ECM510</td><td valign="top">Cell migration</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">SnapGene</td><td valign="top">SnapGene</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015052">SCR_015052</ext-link></td><td valign="top">Sequencing</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">StereoInvestigator</td><td valign="top">Microbrightfield</td><td valign="top"/><td valign="top">Stereology analysis</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ImageJ</td><td valign="top">ImageJ</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link></td><td valign="top">WB data analysis</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Prism8</td><td valign="top">Graphpad</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="top">Statistics and graphs</td></tr><tr><td valign="top">Other</td><td valign="top">Hoechst 33342</td><td valign="top">Invitrogen <break/>Thermo</td><td valign="top">H3569</td><td valign="top">1:1000</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animal models</title><p>All procedures involving animals were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines at University of California, Irvine (UCI). All animals used in SCI studies were females of 12–16 weeks of age and were on immunodeficient background, Rag1 (<xref ref-type="fig" rid="fig7">Figure 7</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1</xref> and <xref ref-type="fig" rid="fig7s2">2</xref>) or NOD-scid (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>) mice. Animal care, behavior, and analysis were performed by investigators blinded to groups, and random group allotment was used. Restricted randomization was applied to maintain equal group numbers. Pre-hoc exclusion criteria for stereological or behavioral assessments included: animals with abnormal scores (2 SD outside the cohort mean), unilateral bruising or abnormal force/displacement curves after contusion injury, or documentation of poor transplantation injection. Additionally, animals that exhibited a progressive decline in activity/function (N = 2) were excluded from the study, euthanized and autopsied. No evidence of infection or tumor formation was identified. Animal groups numbers were estimated in base of historical post-hoc power analysis of transplanted hNSC with stereological analyses (<xref ref-type="bibr" rid="bib25">Hooshmand et al., 2009</xref>). Final group numbers used in histological or behavioral analysis are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-2"><title>NSC lines and culture</title><p>All procedures using human cells were conducted in accordance with the Human Stem Cell Research Oversight (hSCRO) committee at UCI, and mNSC generation was approved by IACUC at UCI.</p><p>Multipotent human CNS-derived stem cells (referred to as hNSC) were isolated from 16 to 20 week gestation human fetal brain, and enriched for CD133 stem cell marker, which enhances the NSC population that exhibit neurosphere-initiating capacity by 2000-fold (<xref ref-type="bibr" rid="bib68">Uchida et al., 2000</xref>). Cells derived in this manner retain multipotent capacity for over 20 passages in vitro and differentiate in a site-specific manner upon transplantation, generating neurons, oligodendrocytes, and astrocytes (<xref ref-type="bibr" rid="bib68">Uchida et al., 2000</xref>). Two different cell lines were used in this study, with comparable derivation methods, Stem cells inc 2491.2 (<xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig7">7</xref>) and UCI161 (<xref ref-type="fig" rid="fig4">Figures 4</xref>–<xref ref-type="fig" rid="fig6">6</xref>). No substantial differences between the two different hNSC lines used in this study were observed in vitro, in terms of migration, CD133+ cell proportion, C1q novel receptor expression, and multipotency (Piltti et al., in preparation).</p><p>Mouse NSC (mNSC) were derived from single embryos cortices at E11.5–12. Cells were resuspended in DMEM media supplemented with the following ingredients (final concentration in parenthesis): N2 supplement (1×), B27 supplement (1×), bFGF (10 ng/mL), EGF (20 ng/mL), heparin (2 µg/mL), NAC (82 µg/mL), L-Glutamine (292 µg/mL), Na<sup>+</sup> Pyruvate (110 µg/mL) and cultured as small neurospheres for the first three passages, and then switched to hNSC media. hNSC/mNSC were cultured either as neurospheres or in monolayer in growth medium (GM): X-vivo 15 (Fisher) based media or Stemline (Sigma) based media supplemented with the following ingredients: N2 supplement (1×), bFGF (20 ng/mL), EGF (2 ng/mL), LIF (10 ng/mL), heparin (2 µg/mL) and NAC (63 µg/mL). Cultures were fed twice a week and passaged every 1–2 weeks.</p><p>For differentiation, cells were plated on poly-L-ornithine (PLO) (Sigma- 5 μg/mL) and recombinant mouse laminin (Invitrogen-10 μg/mL) coated 8-well glass chamber slides in X-vivo or Stemline differentiation medium (DM): supplemented with GDNF (10 ng/mL), BDNF (PeproTech) (10 ng/mL), bFGF (0.1 ng/mL), Ciprofloxacin (Cellgro) (10 μg/mL), Heparin (2 µg/mL), NAC (63 µg/mL), N2 (1:100) and B27 (1:20) for 14 d in vitro (hNSC), or 3–7 d (mNSC) as described previously (<xref ref-type="bibr" rid="bib53">Piltti et al., 2018</xref>).</p></sec><sec id="s4-3"><title>C1q signaling</title><p>To assess C1q induction of intracellular signaling, hNSC were grown on 9.5 cm<sup>2</sup> multi-well plates at 90% confluence in GM. At 1 d post-plating cells were switched to DM with or without (control) purified C1q at [0.1 nM], [1.0 nM], or [200 nM] concentrations for 15, 30, and 60 min as specified in figure legends. The cells were then collected and homogenized in cell lysis buffer (Cell Signaling Technology) and protein concentration was determined in precleared extracts using the micro BCA assay (Pierce). Phosphoarray analysis was performed with PathScan Intracellular signaling array kit, fluorescence readout (Catalog #7744, Cell Signaling technology) following manufacturers protocol, detecting simultaneously 18 phosphorylated molecules. Briefly, 150 µL of [200 µg/mL] protein lysates were added to the nitrocellulose-coated glass slides and incubated overnight at 4°C with gentle rocking motion, followed by exposure to the detection antibody cocktail for 1 hr room temperature (RT). Next, DyLight 680-linked streptavidin secondary antibody was added for 30 min at RT. The slides where analyzed in a LICOR CLx slide scanner and the fluorescence intensity measured for single spots. Samples were normalized to internal positive control spots and then to control conditions (DM without C1q). All experiments were performed using biological triplicates with technical duplicates.</p><p>To verify C1q induction of p-ERK and p-Akt signaling, cells were incubated with C1q for 60 min, total proteins were collected and homogenized with RIPA buffer (Sigma) containing protease (cOmplete ULTRA- Roche) and phosphatase (PhosSTOP-Roche) inhibitors. Equal amount of proteins (10 ug) were resolved in SDS-PAGE precast 4–12% gradient gels (NuPAGE Bis-Tris Gel; Life Technologies), transferred onto Nitrocellulose Pre-Cut Blotting Membranes NuPAGE (Life Technologies) in a semi-dry chamber (Trans-Blot SD Semi-Dry Cell, Bio-Rad), and immunoblotted. Antibodies against p-Akt, p-ERK, and β-actin were used for immunodetection. Bound antibodies were visualized using HRP-coupled secondary antibodies, followed by detection of labeled proteins using SuperSignal West Dura ECL kit (Pierce) and ChemiDoc imaging system (Bio-Rad). Optical band intensities were obtained using ImageJ software (National Institutes of Health; <ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/nih-image/">https://imagej.nih.gov/nih-image/</ext-link>). Band intensities were normalized to those of β-actin and subsequent normalization to untreated control conditions standardized at one and compared to control using one-sample t-test. All antibodies, sources, and dilutions are provided in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. To assess p-ERK signaling pathway blockade, cells were grown as before and treated with p-ERK/MAPK pathway inhibitor (PD98059 −10 µM, GIBCO, catalog # PHZ1164) and with or without (control) C1q[200 nM] for 60 min. Samples were processed as explained above. All experiments were performed using biological triplicates.</p></sec><sec id="s4-4"><title>Far western blot analysis</title><p>To qualitatively determine the ability of C1q to interact with proteins from hNSC, a far-western blot was performed. In this assay, hNSC proteins from the total or cell surface fraction (below) were resolved in SDS-PAGE precast 4–12% gradient gels and transferred onto nitrocellulose pre-cut membranes in a semiwet chamber as described above. Immobilized proteins were incubated with or without C1q 25 µg/mL for 2 hr RT. Bound C1q was identified by imumunodetection, with anti-C1q antibody (monoclonal mouse anti C1q, 1:50, Abcam ab71940) 1 hr at room temperature, followed by anti mouse HRP-conjugated secondary antibody (ECL sheep anti-mouse IgG, HRP-linked whole antibody, 1:5,000, NA931V, GE Healthcare Life Sciences). Bound antibodies were visualized as described above.</p><p>Total protein was extracted with RIPPA buffer as described above. Cell surface proteins were purified using cell surface protein biotinylation assay. hNSC grown in monolayer were incubated with EZ-LinkSulfo-NHS-SS-Biotin (Thermo) following manufacturer’s instructions. Briefly, cells were washed with PBS (supplemented with 0.1 mM Ca<sup>+2</sup> and 1 mM Mg<sup>+2</sup>) 3 times for 5 min at 4°C and then incubated with biotin 1 mg/mL in PBS (0.1 mM Ca<sup>+2</sup> and 1 mM Mg<sup>+2</sup>) for 30 min at 4°C. Biotin was then quenched with glycine 100 mM in PBS (0.1 mM Ca<sup>+2</sup> and 1 mM Mg<sup>+2</sup>) for 30 min at 4°C. Cells then where washed with PBS and lysed with 200 µL/well Tris-HCl 50 mM, pH 7.5; NaCl 100 mM, Triton-100 0.5% v/v lysis buffer, with protease and phosphatase inhibitors cocktail (ROCHE), as described above for total protein extractions.</p></sec><sec id="s4-5"><title>C1q-protein interaction pull-down</title><p>To identify C1q binding proteins from hNSC total fraction, 100 µg of C1q was reversibly biotinylated with Ez-link Sulfo-NHS-SS-Biotinylation kit (Thermo) following the manufacturer’s instructions. Briefly, to form C1q-biotin stock, 1 mg C1q (My Biosource) was resuspended in 2 mL Milli-Q H<sub>2</sub>O and buffer exchanged to PBS using a Zeba spin desalting column 7K MWCO (Thermo) following manufacturer’s instruction. Briefly, 200 µL of C1q stock (500 µg/mL = 0.25 nmol C1q) was incubated with a 20-fold molar excess of biotin reagent. 0.25 × 20 = 5 nmol of Sulfo-NHS-SS-Biotin for 2 hr 4°C in agitation. The un-bound biotin was eliminated by buffer exchange to PBS using a Zeba spin desalting column 7K MWCO (200 µL final volume). About 5 µL aliquot was used to determine C1q protein concentration by BCA analysis. A total of 60–80% of the original amount of C1q was recovered after the biotinylation process. An aliquot of the biotinylated C1q was analyzed by western blot to identify biotinylated C1q (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>); 50 µg of biotinylated C1q was utilized for pull-down experiments (Pierce Pull-Down biotinylated protein-protein interaction kit; Thermo). Briefly, 50 µg of biotinylated C1q (bait protein) was immobilized to a streptavidin agarose bead column for 30 min at 4°C with gentle agitation. The excess bait protein was removed by centrifugation, and then the not bound (available) streptavidin sites were blocked with free biotin (non-reactive). C1q-hNSC protein interactions were captured by incubation of immobilized C1q with 50 µg of hNSC total protein extract (prey proteins), for 2 hr at 4°C. Non-specific protein-interactions were removed by multiple washing steps. To finally elute and recover the attached proteins, the C1q attached to streptavidin columns was incubated with 1 mM DTT for 10 min, to break the SS bond of C1q to biotin (Sulfo-NHS-SS-Biotin) and recover all bound proteins. An aliquot of the elution was analyzed by SDS PAGE/silver staining and western blot to identify the bound proteins and recovered C1q (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Three experimental conditions were included in the pull-down experiments: Condition I: control, bait protein only, to verify C1q binding to the streptavidin column. Condition II: control, no bait protein, to identify unspecific interaction to the streptavidin column. Condition III: experiment, bait (C1q) and prey proteins (hNSC total protein lysate) to identify C1q hNSC-protein interaction. Bound proteins were eluted, trypsinized, and peptides identified using Mass Spectrometry (nanoLC-MS/MS) using a LTQ Orbitrap Velos Pro spectrometer [in the UCI Center for Virus Research Protein Mass Spectrometry Facility]. Proteins identified with high confidence in condition III, but not in conditions I and II, were considered to be associated with C1q specifically. Other controls were performed to validate this experimental procedure. Correct biotinylation of C1q was assessed by western blot analysis and ABC reaction (that identified only biotinylated C1q, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>). Binding ability of biotinylated-C1q versus naïve-C1q was assessed by far-western blot (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C–E</xref>).</p></sec><sec id="s4-6"><title>C1q cross-linking in live cells and pull-down</title><p>To assess C1q cell surface interactions in a biologically relevant setting where the 3D structure of ligand and receptor/s is maintained, we designed a different protein-protein interaction approach. In this strategy, cell surface interactions were assessed in live cells. Briefly, cells were grown in monolayer at 90% confluency, washed with (PBS 0.1 mM Ca+2 1 mM Mg+2) two times and incubated with 10 nM C1q in (PBS 0.1 mM Ca+2 1 mM Mg+2) at 4°C for 1 hr with gentle agitation. Bound C1q was cross-linked with a 20-fold molar excess of a cell impermeable cross-linker (Sulfo EGS Thermo) with an spacer arm of 16.1 A° to cross-link only closely interacting proteins following manufacturer’s instructions. Sulfo EGS was added at a final concentration of 2 mM with bound C1q for 2 hr at 4°C. The cross-linker was quenched with quenching solution to a final concentration of 20 mM for 15 min at 4°C. Cells were then washed twice with (PBS 0.1 mM Ca+2 1 mM Mg+2 glicine 10 mM) and with PBS followed by cell lysis. Cells were lysed in Tris-HCl 50 mM, pH 7.5; NaCl 100 mM, Triton-100 0.5% v/v lysis buffer, with protease and phosphatase inhibitors cocktail (ROCHE) as described above. Pre-cleared extracts were then pulled down with immobilized anti C1q antibody ([JL-1] catalog # ab71940 Abcam). For the pull-down assay, C1q antibody was previously biotinylated with Ez-link Sulfo-NHS-SS-Biotinylation kit (Thermo) following the manufacturer’s instructions and inmobilized as the bait protein in the Pierce Pull-Down biotinylated protein: protein interaction kit (Thermo) as described previously for C1q. To summarize, membrane proteins cross-linked with C1q were extracted and then pulled down with anti-C1q antibody. Conducted bound proteins were eluted and analyzed by mass spectrometry (nanoLC-MS/MS) at the UCI Center for Virus Research Protein Mass Spectrometry Facility, as described above.</p></sec><sec id="s4-7"><title>RNA extraction, and RT-PCR, PCR</title><p>Total RNA was isolated from cell culture samples using RNeasy Mini Kit (Qiagen), followed by elimination of genomic DNA using DNA-free DNase I (Ambion). For RT-PCR cDNA synthesis was performed using High Capacity cDNA Reverse Transcription Kit (ABI Life Technologies) according to the manufacturers protocol. For each PCR reaction 200 ng of cDNA was amplified using GoTaq green Master mix (Promega), in thermal cycler conditions of 2 min 95°C, followed by 35 repeated cycles of 30 min at 95°C 30 min at 58°C and 1 min at 72°C and a final elongation step of 10 min at 72°C. Primers used for C1q novel candidate receptor gene expression are listed in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></sec><sec id="s4-8"><title>Human embryonic cortex single-cell RNA-seq dataset analysis</title><p>Human embryonic cortex (weeks 22–23) single-cell RNA-seq dataset (GSE103723) was downloaded from GEO and processed according to the original publication (<xref ref-type="bibr" rid="bib19">Fan et al., 2018</xref>) using Seurat (<xref ref-type="bibr" rid="bib65">Stuart et al., 2019</xref>). Briefly, UMAP clustering was performed and all cells were classified into three major groups, namely, neurons, glial cells and non-neural based on global gene expression. Subsequently, glia cells were further processed and categorized into major glia types (e.g. Radial glia (NSC), Astrocyte Precursor Cells (APC)-Astrocytes, Oligoprogenitors (OPCs), and Oligodendrocytes) employing customized glia cell specific marker genes enrichment analysis implemented in hypeR (<xref ref-type="bibr" rid="bib21">Federico and Monti, 2019</xref>). Glia cell type specific gene expression of the five candidate receptors were visualized by R package Pheatmap v1.012.</p></sec><sec id="s4-9"><title>Proximity ligation assay (PLA) for C1q interaction with signaling candidates</title><p>To verify C1q-candidate receptor protein interaction, hNSC were dissociated into single cells and plated on eight-well glass chamber slides in GM, 1 d post plating cells were incubated with purified C1q at 10 nM, 100 nM, or 200 nM concentration for 30 min as specified in figure legends. Cells were then fixed with 4% PFA for 15 min RT and cell membranes were stained with wheat germ agglutinin (WGA-Alexa conjugate 488- Invitrogen) (1:200 dilution) for 30 min followed by PLA analysis using the Duolink in situ Red starter kit Mouse/Rabbit (DUO92101, Sigma) according to the manufacturer’s protocol. Briefly, cells were blocked for 30 min at 37°C with blocking solution. Primary antibodies were incubated for 2 hr at room temperature (antibody concentrations and sources in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), washed, then incubated with species-specific secondary antibody-complementary PLA probes (1:5) for 60 min at 37°C in humidified chambers. PLA probes were then ligated for 30 min at 37°C, and amplified at 37°C for 100 min. The slides were cover-sliped with Duolink in situ mounting media with DAPI (Sigma). For analysis, 13 random pictures per condition were captured using an ApoTome microscope system (Zeiss) as a total of 21 z-stacks of optical slices in 0.275 μm intervals using 40× objective. The number of red positive punctae was assessed using the ‘analyze particles’ function in the Image J analysis software, and reported relative to the total number of cells per picture frame. This quantification gives a rough number of average fluorescent particles per cell. All PLA data are shown as the average fluorescent punctae per picture relative to total number of cells per image (13 random images). All experiments were done with biological duplicates and technical duplicates.</p></sec><sec id="s4-10"><title>C1q induction of hNSC motility and chemotaxis</title><p>C1q induction of cell motility was evaluated in a live-cellimaging setting, mNSC were plated into custom-made PDMS microwells at density of 100 cells/microwell and imaged using VivaView FL Incubator Microscope (Olympus America, Inc) at +37°C and 5% CO<sub>2</sub> with 20× objective in 20 min intervals for 7 d as previously described (<xref ref-type="bibr" rid="bib53">Piltti et al., 2018</xref>). Time-lapse images of cells grown in DM, in the presence or absence (control) of C1q at [0.1 nM], [1.0 nM], and [200 nM] concentrations were compiled into movies and for each experiment 20 randomly selected individual cells (total of 60 cells per group) were manually tracked frame-by-frame using Imaris software 7.5.2 (Bitplane) as previously described (<xref ref-type="bibr" rid="bib53">Piltti et al., 2018</xref>). Kinetics analysis was done using Imaris software to track cell motility over time. All data were normalized to control conditions. All experiments were conducted in biological triplicates.</p><p>C1q induction of hNSC chemotaxis was evaluated in transwell assays, hNSC and mNSC were grown as monolayer and dissociated as single cells. Source and concentration of C1q, and inhibitors used are indicated in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. To perform the chemotaxis assay, single cells were resuspended in DM to a concentration of 300,000 cells/mL and then 100 µL of this single-cell resuspension was added to each migration assay chamber, before placing chambers into feeder trays (Millipore) containing 150 µL of media for each condition; the chambers were then incubated at 37°C for 3.5 hr. Subsequently, the chambers were transferred onto new 96-well trays containing 150 µL of prewarmed cell detachment buffer and incubated for 30 min at 37°C. At the end of this incubation, 50 µL 1:75 dilution of CyQuant GR Dye:Lysis buffer was added to the cell detachment buffer and incubated for 15 min at room temperature. Finally, 150 µL CyQuant GR Dye:Lysis/detachment solution was transferred to a new 96-well plate, and migration was quantified using a 480/520 nm filter set on a fluorescent plate reader. To obtain fluorescence standardization, cells of known doses, as well as blanks containing only cell detachment buffer, lysis buffer, or CyQuant Dye, were used. All experiments were conducted in biological triplicate or quadruplicate with technical triplicates.</p></sec><sec id="s4-11"><title>Cell fate and proliferation analysis</title><p>To assess the effect of purified C1q on hNSC proliferation and differentiation hNSC were dissociated and plated as single cells on eight-well glass chamberslides. At 1 d post-plating, GM was changed to DM with or without (control) purified C1q at [0.1 nM], [1.0 nM], or [200 nM] concentrations with or without Brdu/EdU [10 mM] (proliferation). Cells were maintained in DM for 2 d in vitro (DIV) for proliferation and 14DIV for differentiation. hNSC were then fixed with 4% paraformaldehyde (PFA), permeabilized, and blocked in PBS solution supplemented with 0.1% Triton X-100 (Sigma-Aldrich), 5% goat or donkey serum (Jackson ImmunoResearch), and 1% BSA (Sigma-Aldrich). Primary and secondary antibodies including bromodeoxyuridine (Brdu), glial fibrillary acidic protein (GFAP), Olig2, and βIII-tubulin, sources, and the dilutions at which they were used are listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Hoechst 33342 (1:1000 dilution; Invitrogen) was used as a nuclear counterstain. Fluorescent images of immunostained slides were captured using random sampling with either an inverted Olympus IX71 fluorescent microscope or a ZEISS Axio Imager two light microscope with an Apotome2 image processor with 20× objective. Cell quantification was performed using Imaris software. All image capture and cell quantification was performed by investigators blinded to the study groups. All experiments in which hNSC were used were conducted in biological triplicate or quadruplicate with technical duplicates.</p></sec><sec id="s4-12"><title>CRISPR Cas9 hNSC CD44 genetic deletion</title><p>Our previous experimental data on hNSC behavior in vitro and in vivo after transplantation have utilized tissue-derived multipotent cells (<xref ref-type="bibr" rid="bib12">Cummings et al., 2005</xref>; <xref ref-type="bibr" rid="bib58">Salazar et al., 2010</xref>; <xref ref-type="bibr" rid="bib62">Sontag et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Nguyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib13">Cummings et al., 2006</xref>; <xref ref-type="bibr" rid="bib25">Hooshmand et al., 2009</xref>; <xref ref-type="bibr" rid="bib52">Piltti et al., 2013</xref>), and not neuralized induced pluripotent or embryonic stem cells as a starting point. These cells are heterogenous at the time of gene editing, and isogenic clone selection carries a greatly heightened risk of inadvertent deletion of cell subpopulations or types. Accordingly, we developed a different strategy to derive CD44 WT and KO hNSC, using fluorescence activated cell sorting (FACS) to select WT and KO cell populations after CRISPR.</p><p>CD44 WT and KO hNSC were generated by gene editing with CRISPR Cas9 technology. Cas9 plasmid and guide RNAs were custom generated and validated in human HEK293 cells by applied stem cells <ext-link ext-link-type="uri" xlink:href="https://www.appliedstemcell.com/">https://www.appliedstemcell.com/</ext-link>. Briefly, two guide RNAs (gRNA) per gene were individually cloned into a bicistronic vector for co-expression with the Cas9 protein. Following vector delivery into HEK293 cells, the abilities of these gRNAS to guide Cas9 to target sites and promote double strand breaks were evaluated via Sanger sequencing (guide RNA sequences in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Briefly, hNSC were nucleofected at 80% efficiency (Lonza nucleofector buffer L) and co-transfected with two Cas9-GFP plasmids containing the gRNAs CD44g1 and CD44g5 to generate a 47 bp deletion of CD44 gene in exon 2. Unmodified hNSC exhibit 99.1% of CD44+ cells and 1.87% CD44- cells. Two weeks after CRISPR Cas nine modification, 39% of the cells remained positive for CD44 (WT) and 30% exhibited a negative expression (KO). CD44 WT and KO hNSC were then separated and enriched by fluorescence activated cell sorting (FACS). The gating parameters were highly stringent to avoid any heterozygous cell populations in our sorted cell pools (cells exhibiting low expression of CD44). CD44 expression was validated in WT and KO CRISPR Cas9-generated hNSC by flow cytometry (described below), total protein extraction and western blot, and Immunocytochemistry as described above, 2 weeks and 1–2 months after sorting respectively, corroborating stable CD44 WT and KO expression. Antibodies, catalog numbers and dilutions used in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Two different CD44 KO lines were generated with the same method. No substantial differences between the two different cells lines generated regarding their CD133+ content, multipotency, proliferative capacity, differentiation profiles or responses to inflammatory components, like PMN-CM induced migration. Follow up experiments in vitro were done only for the transplanted cell line with biological triplicates or quadruplicates. Additionally, CD44 WT and KO cell lines were sequenced and genotype validating effective CRISPR Cas9 modification and homozygous generation of CD44 KO cell lines and maintenance of the WT genotype in the non-modified cells (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Furthermore, CD133+ marker expression was unchanged in unmodified (WT) versus modified (KO) hNSC (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3C,D</xref>), suggesting that CRISPR Cas9 modification did not substantially alter hNSC ‘stemness’. No karyotype abnormalities (analyzed by cell line genetics <ext-link ext-link-type="uri" xlink:href="https://www.clgenetics.com/">https://www.clgenetics.com/</ext-link>) were observed in the WT and KO lines (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A,B</xref>).</p></sec><sec id="s4-13"><title>CD44 and CD133 flow cytometry</title><p>Cells grown in monolayer were dissociated as single cells and resuspended in PBS supplemented with 10% HSA (Octapharma); cells were then blocked with FcR blocking reagent (Miltenyi Biotec) and incubated with Pre-conjugated anti-CD44-PE (1:11, 130-110-293, Miltenyi Biotec) and anti-CD133/1 antibody (1:11, 130-113-673-FITC, Miltenyi Biotec) for 30 min at 4°C. After washes in PBS supplemented with 10% HSA the cells were analyzed using a BD LSR II Flow Cytometer (BD Biosciences). Cell viability was detected by propidium iodide (PI, 1:1000- Invitrogen) in unstained cells. In all conditions cell viability was typically more than 96%. Gating for all flow cytometry analyses were set using unstained controls, single labeled cells, and PI+ cells.</p></sec><sec id="s4-14"><title>Spinal cord contusion injuries for hNSC acute transplantations</title><p>Immunodeficient mice were anesthetized using 2.5% isofluorane and received a laminectomy at the thoracic vertebrae 9 (T9) using a surgical microscope. All animals received 50 kilodyne (kD; one dyne = 10 µN) contusion injury using the Infinite Horizon Impactor (Precision Systems and Instrumentation), as previously described (<xref ref-type="bibr" rid="bib25">Hooshmand et al., 2009</xref>). For hNSC transplantation immunodeficient mice were used to enable long-term hNSC engraftment. NOD-scid, and Rag1 mice exhibit deficits in adaptive immunity, however, they demonstrate innate immune responses and histopathological characteristics comparable to other mouse strains following SCI (<xref ref-type="bibr" rid="bib36">Luchetti et al., 2010</xref>). Number of animals per group/strain and exclusions are detailed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. hNSC were dissociated into a single-cell suspension and concentrated to a final density of 75,000 cells/µL in X-vivo media-(vehicle) on the day of SCI, and transplants were conducted, as described previously (<xref ref-type="bibr" rid="bib25">Hooshmand et al., 2009</xref>; <xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). Briefly, siliconized beveled glass pipettes (bevel: inner diameter = 70 µm, outer diameter = 100–110 µm; Sutter Instruments) were loaded with freshly triturated hNSC or vehicle, and injections were made into the intact parenchyma (two sites bilaterally above and below the injury epicenter) at T9 using a NanoInjector system and micropositioner (WPI Instruments) immediately after SCI contusion. Each site received 250 nL of cells or vehicle as described (<xref ref-type="bibr" rid="bib12">Cummings et al., 2005</xref>). Previous studies in our laboratory have demonstrated that this volume does not exacerbate damage to the spinal cord.</p></sec><sec id="s4-15"><title>C1q neutralization in vivo</title><p>Immediately after injury, about 2 µL of C1q neutralizing antibody (C1qNab) goat anti-C1q [100 µg/mL], control goat anti-IgG antibody [100 µg/mL] (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>), or vehicle (media in which antibodies were prepared) were delivered via epicenter injections using a Hamilton Flexifil Syringe over 2 min, followed by a 1 min delay prior to withdrawal of syringe. The effect of C1qNAb at the concentration delivered in vivo was first tested in vitro, and no toxic or proliferative effects associated with exposure of hNSC to the C1qNAb was observed. Animals were randomly assigned to receive either C1qNAb with hNSC or vehicle with hNSC. The number of animals per group and exclusions are detailed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-16"><title>Histology and stereological quantification</title><p>At 6WPI, 12WPI or 16WPI (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for different animal cohorts) mice were terminally anesthetized, transcardially perfused with PBS, followed by 4% PFA. Spinal cord regions corresponding to dorsal roots at T2–T6, T6–T12, and T12-L2 were post-fixed and cryoprotected overnight in 4% PFA plus 20% sucrose and, flash frozen at −55°C in isopentane, and stored at −80°C until tissue processing (<xref ref-type="bibr" rid="bib25">Hooshmand et al., 2009</xref>; <xref ref-type="bibr" rid="bib26">Hooshmand et al., 2017</xref>). T6–T12 spinal sections were embedded in Neg50 Frozen Section Medium (Thermo) and 30 µm thick transverse-coronal sections where sectioned in a Cryostat with a CryoJane tape transfer system (Leica), as previously described (<xref ref-type="bibr" rid="bib3">Anderson et al., 1996</xref>; <xref ref-type="bibr" rid="bib62">Sontag et al., 2014</xref>). Frozen sections were collected on slides and stored at −20°C until processed for immunohistochemistry. All sectioning and immunohistochemistry procedures were conducted, as previously described (<xref ref-type="bibr" rid="bib3">Anderson et al., 1996</xref>; <xref ref-type="bibr" rid="bib62">Sontag et al., 2014</xref>). and dilutions used in immunohistochemistry are listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Unbiased histological quantification was conducted using stereology by investigators blinded to experimental groups. A random set of animals (n = 6/group) were selected for cell counts. The optical fractionator probe (<xref ref-type="bibr" rid="bib28">Joelving et al., 2006</xref>) was used for estimation of the number of hNSC (STEM121+) and human astrocytes (STEM123+) in StereoInvestigator (Microbrightfield). Grid size measurements were determined based on preliminary experimentation to establish a low coefficient of error (CE ≤0.08). Cell migration was reported as the total estimated number of cells per 1 mm section, in a distribution graph was the injury epicenter is defined as the area of the cord with the largest Fibronectin positive area. A Cavalieri probe (grid size, 20 × 20 µm<sup>2</sup>, MicroBrightField) was used to estimate total volumes of, spinal cord, fibronectin+ lesion volume, STEM121+, and STEM123+ cell clustering in 1 of 12 intervals from coronal spinal cord sections 360 µm apart, at 10× magnification.</p></sec><sec id="s4-17"><title>Detection of C1q at the SCI epicenter</title><p>A 4-month-old Rag1 female mice received either a laminectomy (control; n = 4) or a moderate contusion injury (50 kD; n = 12) at the thoracic level T9, as described below. Mice were PBS perfused 3 hr (n = 4), 24 hr (n = 4) or 9 d (n = 4) following SCI or laminectomy and the spinal cord freshly dissected and divided into 3 mm segments centered at T9, and two sequential 3 mm segments extending rostral and caudal from T9. Total protein extraction was performed with T-PER buffer (SIGMA) supplemented with protease (cOmplete ULTRA- Roche) and phosphatase (PhosSTOP-Roche) inhibitors. Protein concentration was determined in precleared extracts as described above. 10 µg of protein of the central (T9 or laminectomy) and the farthest rostral and caudal sections were resolved in SDS-PAGE precast 4–12% gradient gels, transferred onto nitrocellulose membranes and immunoblotted as described above. Antibodies against C1q and β-actin are listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Bound antibodies were visualized and analyzed as described above.</p></sec><sec id="s4-18"><title>Behavioral tasks and assessments of locomotor recovery</title><p>All behavioral data were collected and analyzed by blinded observers. Gross locomotor recovery in mice (n = 10/group; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) was assessed using the Basso Mouse Scale (BMS; <xref ref-type="bibr" rid="bib6">Basso et al., 2006</xref>) during the following time points: pre-injury and 2 d/7 d/2 weeks/4 weeks/6 weeks/8 weeks/12 weeks/16 weeks post-injury. Additionally, more sensitive behavioral parameters were utilized, including horizontal ladder beam and CatWalk gait analysis to assess kinematic parameters (<xref ref-type="bibr" rid="bib31">Koopmans et al., 2005</xref>). Horizontal ladder beam and CatWalk tasks were performed pre-injury and every 4 weeks after injury until animals were sacrificed 16 weeks post-injury.</p></sec><sec id="s4-19"><title>Statistics</title><p>For in vitro assays, experiments were performed with biological replicates and technical replicates, as stated in each method section or figure legend. Biological replicates are defined as experiments performed independently from different cell samples (e.g., different cell culture, passage). Technical replicates are defined as experiments performed in duplicates or triplicates with the same cell samples (e.g., same culture sample). We used N3-4 biological replicates consistent with accepted standard for in vitro studies. Statistics were performed using Prism, version 8.0 (Graphpad Software Inc, San Diego, CA, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">http://www.graphpad.com</ext-link>). All data are presented as mean ± standard error of the mean (SEM). When indicated experimental values were normalized to untreated control conditions and standardize to 1 or 100%. Data were analyzed using one-sample t-test to compare with control and Student’s t-test to compare between experimental conditions. When comparing across multiple groups, one-way ANOVA was conducted first, followed by Tukey’s multiple t-test comparisons. In all statistical analyses, significance was defined as p≤0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors are grateful to Rebecca Nishi, MS, Javier Lepe, BS, Chris Nelson, BA, Hongli Liu, MD, for assistance with SCI surgeries and BMS behavioral open field test. The authors thank students Karishma Kumar, Jason Bahremand, BS, Rami Fadi Halaseh, BS, and Phoebe Bui BS, for cell quantification and behavioral analysis. This work was supported by NIH shared instrumentation grant to PDG, as well as grants from the Craig H Nielsen Foundation and the Christopher Reeve Foundation to AJA.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Software, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: All procedures involving animals were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines at University of California, Irvine (UCI). protocols AUP-17-071, AUP 17-115 All procedures using human cells were conducted in accordance with the Human Stem Cell Research Oversight (hSCRO) committee at UCI, hSCRO: protocols 2006-5294 for In vivo transplants, 2007-5493 for in vitro work. mNSC generation was approved by IACUC at UCI. Protocols AUP 17-115.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Number of animals per group for in vivo studies.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-55732-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of antibodies and concentrations used for immunodetection.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-55732-supp2-v2.docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of conditions used in vitro for migration, proliferation, fate, and signaling assay.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-55732-supp3-v2.docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of primers used in this manuscript.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-55732-supp4-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-55732-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p><p>The following previously published dataset was used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Single cell RNA-seq analysis of human embryonic cortex</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL20301">GSE103723</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostinis</surname> <given-names>C</given-names></name><name><surname>Bulla</surname> <given-names>R</given-names></name><name><surname>Tripodo</surname> <given-names>C</given-names></name><name><surname>Gismondi</surname> <given-names>A</given-names></name><name><surname>Stabile</surname> <given-names>H</given-names></name><name><surname>Bossi</surname> <given-names>F</given-names></name><name><surname>Guarnotta</surname> <given-names>C</given-names></name><name><surname>Garlanda</surname> <given-names>C</given-names></name><name><surname>De Seta</surname> <given-names>F</given-names></name><name><surname>Spessotto</surname> <given-names>P</given-names></name><name><surname>Santoni</surname> <given-names>A</given-names></name><name><surname>Ghebrehiwet</surname> <given-names>B</given-names></name><name><surname>Girardi</surname> <given-names>G</given-names></name><name><surname>Tedesco</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development</article-title><source>The Journal of Immunology</source><volume>185</volume><fpage>4420</fpage><lpage>4429</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903215</pub-id><pub-id pub-id-type="pmid">20810993</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aimone</surname> <given-names>JB</given-names></name><name><surname>Leasure</surname> <given-names>JL</given-names></name><name><surname>Perreau</surname> <given-names>VM</given-names></name><name><surname>Thallmair</surname> <given-names>M</given-names></name><collab>Christopher Reeve Paralysis Foundation Research Consortium</collab></person-group><year iso-8601-date="2004">2004</year><article-title>Spatial and temporal gene expression profiling of the contused rat spinal cord</article-title><source>Experimental Neurology</source><volume>189</volume><fpage>204</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.05.042</pub-id><pub-id pub-id-type="pmid">15380473</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>AJ</given-names></name><name><surname>Su</surname> <given-names>JH</given-names></name><name><surname>Cotman</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay</article-title><source>The Journal of Neuroscience</source><volume>16</volume><fpage>1710</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.16-05-01710.1996</pub-id><pub-id pub-id-type="pmid">8774439</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>AJ</given-names></name><name><surname>Robert</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>W</given-names></name><name><surname>Young</surname> <given-names>W</given-names></name><name><surname>Cotman</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activation of complement pathways after contusion-induced spinal cord injury</article-title><source>Journal of Neurotrauma</source><volume>21</volume><fpage>1831</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1089/neu.2004.21.1831</pub-id><pub-id pub-id-type="pmid">15684772</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname> <given-names>ND</given-names></name><name><surname>Marwick</surname> <given-names>JA</given-names></name><name><surname>Vendrell</surname> <given-names>M</given-names></name><name><surname>Rossi</surname> <given-names>AG</given-names></name><name><surname>Dransfield</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The &quot;Phagocytic Synapse&quot; and Clearance of Apoptotic Cells</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>1708</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01708</pub-id><pub-id pub-id-type="pmid">29255465</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname> <given-names>DM</given-names></name><name><surname>Fisher</surname> <given-names>LC</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name><name><surname>Jakeman</surname> <given-names>LB</given-names></name><name><surname>McTigue</surname> <given-names>DM</given-names></name><name><surname>Popovich</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains</article-title><source>Journal of Neurotrauma</source><volume>23</volume><fpage>635</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1089/neu.2006.23.635</pub-id><pub-id pub-id-type="pmid">16689667</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname> <given-names>KD</given-names></name><name><surname>Nguyen</surname> <given-names>HX</given-names></name><name><surname>Galvan</surname> <given-names>MD</given-names></name><name><surname>Salazar</surname> <given-names>DL</given-names></name><name><surname>Woodruff</surname> <given-names>TM</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment</article-title><source>Brain</source><volume>133</volume><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1093/brain/awp322</pub-id><pub-id pub-id-type="pmid">20085927</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benoit</surname> <given-names>ME</given-names></name><name><surname>Tenner</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>3459</fpage><lpage>3469</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3932-10.2011</pub-id><pub-id pub-id-type="pmid">21368058</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname> <given-names>JJ</given-names></name><name><surname>Getz</surname> <given-names>R</given-names></name><name><surname>Jefferson</surname> <given-names>M</given-names></name><name><surname>Kelemen</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Astrocytes secrete basal Lamina after hemisection of rat spinal cord</article-title><source>Brain Research</source><volume>327</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(85)91507-0</pub-id><pub-id pub-id-type="pmid">3986496</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolliger</surname> <given-names>MF</given-names></name><name><surname>Martinelli</surname> <given-names>DC</given-names></name><name><surname>Südhof</surname> <given-names>TC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The cell-adhesion G protein-coupled receptor BAI3 is a high-affinity receptor for C1q-like proteins</article-title><source>PNAS</source><volume>108</volume><fpage>2534</fpage><lpage>2539</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019577108</pub-id><pub-id pub-id-type="pmid">21262840</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botto</surname> <given-names>M</given-names></name><name><surname>Dell'Agnola</surname> <given-names>C</given-names></name><name><surname>Bygrave</surname> <given-names>AE</given-names></name><name><surname>Thompson</surname> <given-names>EM</given-names></name><name><surname>Cook</surname> <given-names>HT</given-names></name><name><surname>Petry</surname> <given-names>F</given-names></name><name><surname>Loos</surname> <given-names>M</given-names></name><name><surname>Pandolfi</surname> <given-names>PP</given-names></name><name><surname>Walport</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies</article-title><source>Nature Genetics</source><volume>19</volume><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/ng0598-56</pub-id><pub-id pub-id-type="pmid">9590289</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Tamaki</surname> <given-names>SJ</given-names></name><name><surname>Salazar</surname> <given-names>DL</given-names></name><name><surname>Hooshmand</surname> <given-names>M</given-names></name><name><surname>Summers</surname> <given-names>R</given-names></name><name><surname>Gage</surname> <given-names>FH</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice</article-title><source>PNAS</source><volume>102</volume><fpage>14069</fpage><lpage>14074</lpage><pub-id pub-id-type="doi">10.1073/pnas.0507063102</pub-id><pub-id pub-id-type="pmid">16172374</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Tamaki</surname> <given-names>SJ</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Human neural stem cell differentiation following transplantation into spinal cord injured mice: association with recovery of locomotor function</article-title><source>Neurological Research</source><volume>28</volume><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1179/016164106X115116</pub-id><pub-id pub-id-type="pmid">16808875</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deboux</surname> <given-names>C</given-names></name><name><surname>Ladraa</surname> <given-names>S</given-names></name><name><surname>Cazaubon</surname> <given-names>S</given-names></name><name><surname>Ghribi-Mallah</surname> <given-names>S</given-names></name><name><surname>Weiss</surname> <given-names>N</given-names></name><name><surname>Chaverot</surname> <given-names>N</given-names></name><name><surname>Couraud</surname> <given-names>PO</given-names></name><name><surname>Baron-Van Evercooren</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Overexpression of CD44 in neural precursor cells improves trans-endothelial migration and facilitates their invasion of perivascular tissues in vivo</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e57430</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0057430</pub-id><pub-id pub-id-type="pmid">23468987</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Puerto</surname> <given-names>A</given-names></name><name><surname>Díaz-Hernández</surname> <given-names>JI</given-names></name><name><surname>Tapia</surname> <given-names>M</given-names></name><name><surname>Gomez-Villafuertes</surname> <given-names>R</given-names></name><name><surname>Benitez</surname> <given-names>MJ</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Miras-Portugal</surname> <given-names>MT</given-names></name><name><surname>Wandosell</surname> <given-names>F</given-names></name><name><surname>Díaz-Hernández</surname> <given-names>M</given-names></name><name><surname>Garrido</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adenylate cyclase 5 coordinates the action of ADP, P2Y1, P2Y13 and ATP-gated P2X7 receptors on axonal elongation</article-title><source>Journal of Cell Science</source><volume>125</volume><fpage>176</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1242/jcs.091736</pub-id><pub-id pub-id-type="pmid">22250198</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delamarche</surname> <given-names>C</given-names></name><name><surname>Berger</surname> <given-names>F</given-names></name><name><surname>Pouplard</surname> <given-names>A</given-names></name><name><surname>Emile</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>An ELISA technique for the measurement of C1q in cerebrospinal fluid</article-title><source>Journal of Immunological Methods</source><volume>114</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(88)90160-3</pub-id><pub-id pub-id-type="pmid">3141513</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dillon</surname> <given-names>SP</given-names></name><name><surname>D'Souza</surname> <given-names>A</given-names></name><name><surname>Kurien</surname> <given-names>BT</given-names></name><name><surname>Scofield</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systemic lupus erythematosus and C1q: a quantitative ELISA for determining C1q levels in serum</article-title><source>Biotechnology Journal</source><volume>4</volume><fpage>1210</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1002/biot.200800273</pub-id><pub-id pub-id-type="pmid">19370710</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunkelberger</surname> <given-names>JR</given-names></name><name><surname>Song</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Complement and its role in innate and adaptive immune responses</article-title><source>Cell Research</source><volume>20</volume><fpage>34</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/cr.2009.139</pub-id><pub-id pub-id-type="pmid">20010915</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>X</given-names></name><name><surname>Dong</surname> <given-names>J</given-names></name><name><surname>Zhong</surname> <given-names>S</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Yan</surname> <given-names>L</given-names></name><name><surname>Yong</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Qiao</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spatial transcriptomic survey of human embryonic cerebral cortex by single-cell RNA-seq analysis</article-title><source>Cell Research</source><volume>28</volume><fpage>730</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1038/s41422-018-0053-3</pub-id><pub-id pub-id-type="pmid">29867213</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname> <given-names>J-D</given-names></name><name><surname>Lee</surname> <given-names>S-L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Matriptase is required for the active form of hepatocyte growth factor induced met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1843</volume><fpage>1285</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.03.020</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Federico</surname> <given-names>A</given-names></name><name><surname>Monti</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>hypeR: an R package for geneset enrichment workflows</article-title><source>Bioinformatics</source><volume>46</volume><elocation-id>btz700</elocation-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btz700</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname> <given-names>K</given-names></name><name><surname>Hippe</surname> <given-names>A</given-names></name><name><surname>Schmaus</surname> <given-names>A</given-names></name><name><surname>Homey</surname> <given-names>B</given-names></name><name><surname>Sleeman</surname> <given-names>JP</given-names></name><name><surname>Orian-Rousseau</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44</article-title><source>Cell Death &amp; Disease</source><volume>4</volume><elocation-id>e819</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.364</pub-id><pub-id pub-id-type="pmid">24091662</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname> <given-names>M</given-names></name><name><surname>Koda</surname> <given-names>M</given-names></name><name><surname>Ino</surname> <given-names>H</given-names></name><name><surname>Murakami</surname> <given-names>M</given-names></name><name><surname>Yamazaki</surname> <given-names>M</given-names></name><name><surname>Moriya</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Upregulation of osteopontin expression in rat spinal cord microglia after traumatic injury</article-title><source>Journal of Neurotrauma</source><volume>20</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1089/089771503321532879</pub-id><pub-id pub-id-type="pmid">12820683</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herishanu</surname> <given-names>Y</given-names></name><name><surname>Gibellini</surname> <given-names>F</given-names></name><name><surname>Njuguna</surname> <given-names>N</given-names></name><name><surname>Hazan-Halevy</surname> <given-names>I</given-names></name><name><surname>Farooqui</surname> <given-names>M</given-names></name><name><surname>Bern</surname> <given-names>S</given-names></name><name><surname>Keyvanfar</surname> <given-names>K</given-names></name><name><surname>Lee</surname> <given-names>E</given-names></name><name><surname>Wilson</surname> <given-names>W</given-names></name><name><surname>Wiestner</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1</article-title><source>Leukemia &amp; Lymphoma</source><volume>52</volume><fpage>1758</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.3109/10428194.2011.569962</pub-id><pub-id pub-id-type="pmid">21649540</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooshmand</surname> <given-names>MJ</given-names></name><name><surname>Sontag</surname> <given-names>CJ</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Tamaki</surname> <given-names>S</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name><name><surname>Cummings</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Analysis of host-mediated repair mechanisms after human CNS-stem cell transplantation for spinal cord injury: correlation of engraftment with recovery</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e5871</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005871</pub-id><pub-id pub-id-type="pmid">19517014</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooshmand</surname> <given-names>MJ</given-names></name><name><surname>Nguyen</surname> <given-names>HX</given-names></name><name><surname>Piltti</surname> <given-names>KM</given-names></name><name><surname>Benavente</surname> <given-names>F</given-names></name><name><surname>Hong</surname> <given-names>S</given-names></name><name><surname>Flanagan</surname> <given-names>L</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neutrophils induce astroglial differentiation and migration of human neural stem cells via C1q and C3a synthesis</article-title><source>The Journal of Immunology</source><volume>199</volume><fpage>1069</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600064</pub-id><pub-id pub-id-type="pmid">28687659</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hepatocyte growth factor enhances the generation of high-purity oligodendrocytes from human embryonic stem cells</article-title><source>Differentiation</source><volume>78</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.diff.2009.05.008</pub-id><pub-id pub-id-type="pmid">19608329</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joelving</surname> <given-names>FC</given-names></name><name><surname>Billeskov</surname> <given-names>R</given-names></name><name><surname>Christensen</surname> <given-names>JR</given-names></name><name><surname>West</surname> <given-names>M</given-names></name><name><surname>Pakkenberg</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Hippocampal neuron and glial cell numbers in Parkinson's disease--a stereological study</article-title><source>Hippocampus</source><volume>16</volume><fpage>826</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1002/hipo.20212</pub-id><pub-id pub-id-type="pmid">16941622</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashyap</surname> <given-names>T</given-names></name><name><surname>Pramanik</surname> <given-names>KK</given-names></name><name><surname>Nath</surname> <given-names>N</given-names></name><name><surname>Mishra</surname> <given-names>P</given-names></name><name><surname>Singh</surname> <given-names>AK</given-names></name><name><surname>Nagini</surname> <given-names>S</given-names></name><name><surname>Rana</surname> <given-names>A</given-names></name><name><surname>Mishra</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral Cancer</article-title><source>Oral Oncology</source><volume>86</volume><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2018.09.028</pub-id><pub-id pub-id-type="pmid">30409306</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>MZ</given-names></name><name><surname>He</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuro-psychopharmacological perspective of orphan receptors of rhodopsin (class A) family of G protein-coupled receptors</article-title><source>Psychopharmacology</source><volume>234</volume><fpage>1181</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1007/s00213-017-4586-9</pub-id><pub-id pub-id-type="pmid">28289782</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopmans</surname> <given-names>GC</given-names></name><name><surname>Deumens</surname> <given-names>R</given-names></name><name><surname>Honig</surname> <given-names>WM</given-names></name><name><surname>Hamers</surname> <given-names>FP</given-names></name><name><surname>Steinbusch</surname> <given-names>HW</given-names></name><name><surname>Joosten</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The assessment of locomotor function in spinal cord injured rats: the importance of objective analysis of coordination</article-title><source>Journal of Neurotrauma</source><volume>22</volume><fpage>214</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1089/neu.2005.22.214</pub-id><pub-id pub-id-type="pmid">15716628</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname> <given-names>F</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Wong</surname> <given-names>VW</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Lu</surname> <given-names>A</given-names></name><name><surname>Lu</surname> <given-names>W</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hepatocyte growth factor promotes proliferation and migration in immortalized progenitor cells</article-title><source>NeuroReport</source><volume>19</volume><fpage>765</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1097/WNR.0b013e3282fdf69e</pub-id><pub-id pub-id-type="pmid">18418254</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>DK</given-names></name><name><surname>George</surname> <given-names>SR</given-names></name><name><surname>Cheng</surname> <given-names>R</given-names></name><name><surname>Nguyen</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Lynch</surname> <given-names>KR</given-names></name><name><surname>O'Dowd</surname> <given-names>BF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Identification of four novel human G protein-coupled receptors expressed in the brain</article-title><source>Molecular Brain Research</source><volume>86</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S0169-328X(00)00242-4</pub-id><pub-id pub-id-type="pmid">11165367</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Poudel</surname> <given-names>B</given-names></name><name><surname>Ki</surname> <given-names>HH</given-names></name><name><surname>Nepali</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>YM</given-names></name><name><surname>Shin</surname> <given-names>JS</given-names></name><name><surname>Kim</surname> <given-names>DK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complement C1q stimulates the progression of hepatocellular tumor through the activation of discoidin domain receptor 1</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>4908</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-23240-6</pub-id><pub-id pub-id-type="pmid">29559654</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Han</surname> <given-names>SS</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Tuohy</surname> <given-names>TM</given-names></name><name><surname>Xue</surname> <given-names>H</given-names></name><name><surname>Cai</surname> <given-names>J</given-names></name><name><surname>Back</surname> <given-names>SA</given-names></name><name><surname>Sherman</surname> <given-names>LS</given-names></name><name><surname>Fischer</surname> <given-names>I</given-names></name><name><surname>Rao</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>CD44 expression identifies astrocyte-restricted precursor cells</article-title><source>Developmental Biology</source><volume>276</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2004.08.018</pub-id><pub-id pub-id-type="pmid">15531362</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luchetti</surname> <given-names>S</given-names></name><name><surname>Beck</surname> <given-names>KD</given-names></name><name><surname>Galvan</surname> <given-names>MD</given-names></name><name><surname>Silva</surname> <given-names>R</given-names></name><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury</article-title><source>Journal of Neurotrauma</source><volume>27</volume><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1089/neu.2009.0930</pub-id><pub-id pub-id-type="pmid">19831737</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mevorach</surname> <given-names>D</given-names></name><name><surname>Mascarenhas</surname> <given-names>JO</given-names></name><name><surname>Gershov</surname> <given-names>D</given-names></name><name><surname>Elkon</surname> <given-names>KB</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Complement-dependent clearance of apoptotic cells by human macrophages</article-title><source>Journal of Experimental Medicine</source><volume>188</volume><fpage>2313</fpage><lpage>2320</lpage><pub-id pub-id-type="doi">10.1084/jem.188.12.2313</pub-id><pub-id pub-id-type="pmid">9858517</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname> <given-names>AT</given-names></name><name><surname>Sumida</surname> <given-names>T</given-names></name><name><surname>Nomura</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>ML</given-names></name><name><surname>Higo</surname> <given-names>T</given-names></name><name><surname>Nakagawa</surname> <given-names>A</given-names></name><name><surname>Okada</surname> <given-names>K</given-names></name><name><surname>Sakai</surname> <given-names>T</given-names></name><name><surname>Hashimoto</surname> <given-names>A</given-names></name><name><surname>Hara</surname> <given-names>Y</given-names></name><name><surname>Shimizu</surname> <given-names>I</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Toko</surname> <given-names>H</given-names></name><name><surname>Katada</surname> <given-names>A</given-names></name><name><surname>Akazawa</surname> <given-names>H</given-names></name><name><surname>Oka</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>JK</given-names></name><name><surname>Minamino</surname> <given-names>T</given-names></name><name><surname>Nagai</surname> <given-names>T</given-names></name><name><surname>Walsh</surname> <given-names>K</given-names></name><name><surname>Kikuchi</surname> <given-names>A</given-names></name><name><surname>Matsumoto</surname> <given-names>M</given-names></name><name><surname>Botto</surname> <given-names>M</given-names></name><name><surname>Shiojima</surname> <given-names>I</given-names></name><name><surname>Komuro</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Complement C1q activates canonical wnt signaling and promotes aging-related phenotypes</article-title><source>Cell</source><volume>149</volume><fpage>1298</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.047</pub-id><pub-id pub-id-type="pmid">22682250</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naruse</surname> <given-names>M</given-names></name><name><surname>Shibasaki</surname> <given-names>K</given-names></name><name><surname>Yokoyama</surname> <given-names>S</given-names></name><name><surname>Kurachi</surname> <given-names>M</given-names></name><name><surname>Ishizaki</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e53109</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0053109</pub-id><pub-id pub-id-type="pmid">23308146</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauta</surname> <given-names>AJ</given-names></name><name><surname>Trouw</surname> <given-names>LA</given-names></name><name><surname>Daha</surname> <given-names>MR</given-names></name><name><surname>Tijsma</surname> <given-names>O</given-names></name><name><surname>Nieuwland</surname> <given-names>R</given-names></name><name><surname>Schwaeble</surname> <given-names>WJ</given-names></name><name><surname>Gingras</surname> <given-names>AR</given-names></name><name><surname>Mantovani</surname> <given-names>A</given-names></name><name><surname>Hack</surname> <given-names>EC</given-names></name><name><surname>Roos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Direct binding of C1q to apoptotic cells and cell blebs induces complement activation</article-title><source>European Journal of Immunology</source><volume>32</volume><fpage>1726</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(200206)32:6&lt;1726::AID-IMMU1726&gt;3.0.CO;2-R</pub-id><pub-id pub-id-type="pmid">12115656</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>HX</given-names></name><name><surname>Galvan</surname> <given-names>MD</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury</article-title><source>Journal of Neuroinflammation</source><volume>5</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-5-26</pub-id><pub-id pub-id-type="pmid">18578885</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>HX</given-names></name><name><surname>Hooshmand</surname> <given-names>MJ</given-names></name><name><surname>Saiwai</surname> <given-names>H</given-names></name><name><surname>Maddox</surname> <given-names>J</given-names></name><name><surname>Salehi</surname> <given-names>A</given-names></name><name><surname>Lakatos</surname> <given-names>A</given-names></name><name><surname>Nishi</surname> <given-names>RA</given-names></name><name><surname>Salazar</surname> <given-names>D</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Systemic neutrophil depletion modulates the migration and fate of transplanted human neural stem cells to rescue functional repair</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>9269</fpage><lpage>9287</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2785-16.2017</pub-id><pub-id pub-id-type="pmid">28847814</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoleau</surname> <given-names>C</given-names></name><name><surname>Benzakour</surname> <given-names>O</given-names></name><name><surname>Agasse</surname> <given-names>F</given-names></name><name><surname>Thiriet</surname> <given-names>N</given-names></name><name><surname>Petit</surname> <given-names>J</given-names></name><name><surname>Prestoz</surname> <given-names>L</given-names></name><name><surname>Roger</surname> <given-names>M</given-names></name><name><surname>Jaber</surname> <given-names>M</given-names></name><name><surname>Coronas</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Endogenous hepatocyte growth factor is a niche signal for subventricular zone neural stem cell amplification and self-renewal</article-title><source>Stem Cells</source><volume>27</volume><fpage>408</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2008-0226</pub-id><pub-id pub-id-type="pmid">18988709</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okumura</surname> <given-names>S</given-names></name><name><surname>Vatner</surname> <given-names>DE</given-names></name><name><surname>Kurotani</surname> <given-names>R</given-names></name><name><surname>Bai</surname> <given-names>Y</given-names></name><name><surname>Gao</surname> <given-names>S</given-names></name><name><surname>Yuan</surname> <given-names>Z</given-names></name><name><surname>Iwatsubo</surname> <given-names>K</given-names></name><name><surname>Ulucan</surname> <given-names>C</given-names></name><name><surname>Kawabe</surname> <given-names>J</given-names></name><name><surname>Ghosh</surname> <given-names>K</given-names></name><name><surname>Vatner</surname> <given-names>SF</given-names></name><name><surname>Ishikawa</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases akt signal with chronic catecholamine stress</article-title><source>Circulation</source><volume>116</volume><fpage>1776</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.698662</pub-id><pub-id pub-id-type="pmid">17893275</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Organ</surname> <given-names>SL</given-names></name><name><surname>Tsao</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>An overview of the c-MET signaling pathway</article-title><source>Therapeutic Advances in Medical Oncology</source><volume>3</volume><fpage>S7</fpage><lpage>S19</lpage><pub-id pub-id-type="doi">10.1177/1758834011422556</pub-id><pub-id pub-id-type="pmid">22128289</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orian-Rousseau</surname> <given-names>V</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Sleeman</surname> <given-names>JP</given-names></name><name><surname>Herrlich</surname> <given-names>P</given-names></name><name><surname>Ponta</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>CD44 is required for two consecutive steps in HGF/c-Met signaling</article-title><source>Genes &amp; Development</source><volume>16</volume><fpage>3074</fpage><lpage>3086</lpage><pub-id pub-id-type="doi">10.1101/gad.242602</pub-id><pub-id pub-id-type="pmid">12464636</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orian-Rousseau</surname> <given-names>V</given-names></name><name><surname>Schmitt</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CD44 regulates wnt signaling at the level of LRP6</article-title><source>Molecular &amp; Cellular Oncology</source><volume>2</volume><elocation-id>e995046</elocation-id><pub-id pub-id-type="doi">10.4161/23723556.2014.995046</pub-id><pub-id pub-id-type="pmid">27308483</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>D</given-names></name><name><surname>Tosello-Trampont</surname> <given-names>AC</given-names></name><name><surname>Elliott</surname> <given-names>MR</given-names></name><name><surname>Lu</surname> <given-names>M</given-names></name><name><surname>Haney</surname> <given-names>LB</given-names></name><name><surname>Ma</surname> <given-names>Z</given-names></name><name><surname>Klibanov</surname> <given-names>AL</given-names></name><name><surname>Mandell</surname> <given-names>JW</given-names></name><name><surname>Ravichandran</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module</article-title><source>Nature</source><volume>450</volume><fpage>430</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/nature06329</pub-id><pub-id pub-id-type="pmid">17960134</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>SL</given-names></name><name><surname>Nguyen</surname> <given-names>HX</given-names></name><name><surname>Mendez</surname> <given-names>OA</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Complement protein C1q modulates neurite outgrowth in vitro and spinal cord axon regeneration in vivo</article-title><source>Journal of Neuroscience</source><volume>35</volume><fpage>4332</fpage><lpage>4349</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4473-12.2015</pub-id><pub-id pub-id-type="pmid">25762679</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>SL</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Complement and spinal cord injury: traditional and non-traditional aspects of complement cascade function in the injured spinal cord microenvironment</article-title><source>Experimental Neurology</source><volume>258</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2014.04.028</pub-id><pub-id pub-id-type="pmid">25017886</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piao</surname> <given-names>JH</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Duncan</surname> <given-names>ID</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD44 is required for the migration of transplanted oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal cord</article-title><source>Glia</source><volume>61</volume><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1002/glia.22438</pub-id><pub-id pub-id-type="pmid">23280959</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piltti</surname> <given-names>KM</given-names></name><name><surname>Salazar</surname> <given-names>DL</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Safety of human neural stem cell transplantation in chronic spinal cord injury</article-title><source>STEM CELLS Translational Medicine</source><volume>2</volume><fpage>961</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.5966/sctm.2013-0064</pub-id><pub-id pub-id-type="pmid">24191264</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piltti</surname> <given-names>KM</given-names></name><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Carta</surname> <given-names>K</given-names></name><name><surname>Manughian-Peter</surname> <given-names>A</given-names></name><name><surname>Worne</surname> <given-names>CL</given-names></name><name><surname>Singh</surname> <given-names>K</given-names></name><name><surname>Ong</surname> <given-names>D</given-names></name><name><surname>Maksymyuk</surname> <given-names>Y</given-names></name><name><surname>Khine</surname> <given-names>M</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Live-cell time-lapse imaging and single-cell tracking of in vitro cultured neural stem cells - Tools for analyzing dynamics of cell cycle, migration, and lineage selection</article-title><source>Methods</source><volume>133</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2017.10.003</pub-id><pub-id pub-id-type="pmid">29050826</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pluchino</surname> <given-names>S</given-names></name><name><surname>Zanotti</surname> <given-names>L</given-names></name><name><surname>Rossi</surname> <given-names>B</given-names></name><name><surname>Brambilla</surname> <given-names>E</given-names></name><name><surname>Ottoboni</surname> <given-names>L</given-names></name><name><surname>Salani</surname> <given-names>G</given-names></name><name><surname>Martinello</surname> <given-names>M</given-names></name><name><surname>Cattalini</surname> <given-names>A</given-names></name><name><surname>Bergami</surname> <given-names>A</given-names></name><name><surname>Furlan</surname> <given-names>R</given-names></name><name><surname>Comi</surname> <given-names>G</given-names></name><name><surname>Constantin</surname> <given-names>G</given-names></name><name><surname>Martino</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism</article-title><source>Nature</source><volume>436</volume><fpage>266</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/nature03889</pub-id><pub-id pub-id-type="pmid">16015332</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponta</surname> <given-names>H</given-names></name><name><surname>Sherman</surname> <given-names>L</given-names></name><name><surname>Herrlich</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>CD44: from adhesion molecules to signalling regulators</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>4</volume><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/nrm1004</pub-id><pub-id pub-id-type="pmid">12511867</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presumey</surname> <given-names>J</given-names></name><name><surname>Bialas</surname> <given-names>AR</given-names></name><name><surname>Carroll</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Complement system in neural synapse elimination in development and disease</article-title><source>Advances in Immunology</source><volume>135</volume><fpage>53</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2017.06.004</pub-id><pub-id pub-id-type="pmid">28826529</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampon</surname> <given-names>C</given-names></name><name><surname>Weiss</surname> <given-names>N</given-names></name><name><surname>Deboux</surname> <given-names>C</given-names></name><name><surname>Chaverot</surname> <given-names>N</given-names></name><name><surname>Miller</surname> <given-names>F</given-names></name><name><surname>Buchet</surname> <given-names>D</given-names></name><name><surname>Tricoire-Leignel</surname> <given-names>H</given-names></name><name><surname>Cazaubon</surname> <given-names>S</given-names></name><name><surname>Baron-Van Evercooren</surname> <given-names>A</given-names></name><name><surname>Couraud</surname> <given-names>PO</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Molecular mechanism of systemic delivery of neural precursor cells to the brain: assembly of brain endothelial apical cups and control of transmigration by CD44</article-title><source>Stem Cells</source><volume>26</volume><fpage>1673</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2008-0122</pub-id><pub-id pub-id-type="pmid">18450824</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname> <given-names>DL</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Hamers</surname> <given-names>FP</given-names></name><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e12272</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012272</pub-id><pub-id pub-id-type="pmid">20806064</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sassone-Corsi</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cyclic AMP pathway</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a011148</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a011148</pub-id><pub-id pub-id-type="pmid">23209152</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname> <given-names>M</given-names></name><name><surname>Metzger</surname> <given-names>M</given-names></name><name><surname>Gradl</surname> <given-names>D</given-names></name><name><surname>Davidson</surname> <given-names>G</given-names></name><name><surname>Orian-Rousseau</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CD44 functions in wnt signaling by regulating LRP6 localization and activation</article-title><source>Cell Death &amp; Differentiation</source><volume>22</volume><fpage>677</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/cdd.2014.156</pub-id><pub-id pub-id-type="pmid">25301071</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaltouki</surname> <given-names>A</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Rao</surname> <given-names>MS</given-names></name><name><surname>Zeng</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Efficient generation of astrocytes from human pluripotent stem cells in defined conditions</article-title><source>Stem Cells</source><volume>31</volume><fpage>941</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1002/stem.1334</pub-id><pub-id pub-id-type="pmid">23341249</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sontag</surname> <given-names>CJ</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Cummings</surname> <given-names>BJ</given-names></name><name><surname>Anderson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Injury to the spinal cord niche alters the engraftment dynamics of human neural stem cells</article-title><source>Stem Cell Reports</source><volume>2</volume><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2014.03.005</pub-id><pub-id pub-id-type="pmid">24936450</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephan</surname> <given-names>AH</given-names></name><name><surname>Barres</surname> <given-names>BA</given-names></name><name><surname>Stevens</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The complement system: an unexpected role in synaptic pruning during development and disease</article-title><source>Annual Review of Neuroscience</source><volume>35</volume><fpage>369</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113810</pub-id><pub-id pub-id-type="pmid">22715882</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struve</surname> <given-names>J</given-names></name><name><surname>Maher</surname> <given-names>PC</given-names></name><name><surname>Li</surname> <given-names>YQ</given-names></name><name><surname>Kinney</surname> <given-names>S</given-names></name><name><surname>Fehlings</surname> <given-names>MG</given-names></name><name><surname>Kuntz</surname> <given-names>C</given-names></name><name><surname>Sherman</surname> <given-names>LS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Disruption of the hyaluronan-based extracellular matrix in spinal cord promotes astrocyte proliferation</article-title><source>Glia</source><volume>52</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/glia.20215</pub-id><pub-id pub-id-type="pmid">15892130</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname> <given-names>T</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Hoffman</surname> <given-names>P</given-names></name><name><surname>Hafemeister</surname> <given-names>C</given-names></name><name><surname>Papalexi</surname> <given-names>E</given-names></name><name><surname>Mauck</surname> <given-names>WM</given-names></name><name><surname>Hao</surname> <given-names>Y</given-names></name><name><surname>Stoeckius</surname> <given-names>M</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive integration of Single-Cell data</article-title><source>Cell</source><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id><pub-id pub-id-type="pmid">31178118</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>W</given-names></name><name><surname>Foster</surname> <given-names>SC</given-names></name><name><surname>Xing</surname> <given-names>R</given-names></name><name><surname>Feistel</surname> <given-names>K</given-names></name><name><surname>Olsen</surname> <given-names>RH</given-names></name><name><surname>Acevedo</surname> <given-names>SF</given-names></name><name><surname>Raber</surname> <given-names>J</given-names></name><name><surname>Sherman</surname> <given-names>LS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CD44 transmembrane receptor and hyaluronan regulate adult hippocampal neural stem cell quiescence and differentiation</article-title><source>Journal of Biological Chemistry</source><volume>292</volume><fpage>4434</fpage><lpage>4445</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.774109</pub-id><pub-id pub-id-type="pmid">28154169</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tena</surname> <given-names>A</given-names></name><name><surname>Sachs</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Stem cells: immunology and immunomodulation</article-title><source>Developments in Ophthalmology</source><volume>53</volume><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1159/000357360</pub-id><pub-id pub-id-type="pmid">24732766</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Buck</surname> <given-names>DW</given-names></name><name><surname>He</surname> <given-names>D</given-names></name><name><surname>Reitsma</surname> <given-names>MJ</given-names></name><name><surname>Masek</surname> <given-names>M</given-names></name><name><surname>Phan</surname> <given-names>TV</given-names></name><name><surname>Tsukamoto</surname> <given-names>AS</given-names></name><name><surname>Gage</surname> <given-names>FH</given-names></name><name><surname>Weissman</surname> <given-names>IL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Direct isolation of human central nervous system stem cells</article-title><source>PNAS</source><volume>97</volume><fpage>14720</fpage><lpage>14725</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.26.14720</pub-id><pub-id pub-id-type="pmid">11121071</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>TW</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Gyetko</surname> <given-names>MR</given-names></name><name><surname>Parent</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hepatocyte growth factor acts as a mitogen and chemoattractant for postnatal subventricular zone-olfactory bulb neurogenesis</article-title><source>Molecular and Cellular Neuroscience</source><volume>48</volume><fpage>38</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2011.06.003</pub-id><pub-id pub-id-type="pmid">21683144</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname> <given-names>GF</given-names></name><name><surname>Ashkar</surname> <given-names>S</given-names></name><name><surname>Glimcher</surname> <given-names>MJ</given-names></name><name><surname>Cantor</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Receptor-ligand interaction between CD44 and osteopontin (Eta-1)</article-title><source>Science</source><volume>271</volume><fpage>509</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1126/science.271.5248.509</pub-id><pub-id pub-id-type="pmid">8560266</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>L</given-names></name><name><surname>Vatner</surname> <given-names>DE</given-names></name><name><surname>O'Connor</surname> <given-names>JP</given-names></name><name><surname>Ivessa</surname> <given-names>A</given-names></name><name><surname>Ge</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Hirotani</surname> <given-names>S</given-names></name><name><surname>Ishikawa</surname> <given-names>Y</given-names></name><name><surname>Sadoshima</surname> <given-names>J</given-names></name><name><surname>Vatner</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Type 5 adenylyl cyclase disruption increases longevity and protects against stress</article-title><source>Cell</source><volume>130</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.05.038</pub-id><pub-id pub-id-type="pmid">17662940</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonemasu</surname> <given-names>K</given-names></name><name><surname>Kitajima</surname> <given-names>H</given-names></name><name><surname>Tanabe</surname> <given-names>S</given-names></name><name><surname>Ochi</surname> <given-names>T</given-names></name><name><surname>Shinkai</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Effect of age on C1q and C3 levels in human serum and their presence in colostrum</article-title><source>Immunology</source><volume>35</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">700781</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamanian</surname> <given-names>JL</given-names></name><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Foo</surname> <given-names>LC</given-names></name><name><surname>Nouri</surname> <given-names>N</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Giffard</surname> <given-names>RG</given-names></name><name><surname>Barres</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genomic analysis of reactive astrogliosis</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>6391</fpage><lpage>6410</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6221-11.2012</pub-id><pub-id pub-id-type="pmid">22553043</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>LS</given-names></name><name><surname>Ma</surname> <given-names>HW</given-names></name><name><surname>Greyner</surname> <given-names>HJ</given-names></name><name><surname>Zuo</surname> <given-names>W</given-names></name><name><surname>Mummert</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inhibition of cell proliferation by CD44: akt is inactivated and EGR-1 is down-regulated</article-title><source>Cell Proliferation</source><volume>43</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2184.2010.00689.x</pub-id><pub-id pub-id-type="pmid">20590664</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Yan</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>XR</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>FF</given-names></name><name><surname>Jiang</surname> <given-names>XD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury</article-title><source>Journal of Neuroinflammation</source><volume>10</volume><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-10-106</pub-id><pub-id pub-id-type="pmid">23971414</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Sloan</surname> <given-names>SA</given-names></name><name><surname>Bennett</surname> <given-names>ML</given-names></name><name><surname>Scholze</surname> <given-names>AR</given-names></name><name><surname>O'Keeffe</surname> <given-names>S</given-names></name><name><surname>Phatnani</surname> <given-names>HP</given-names></name><name><surname>Guarnieri</surname> <given-names>P</given-names></name><name><surname>Caneda</surname> <given-names>C</given-names></name><name><surname>Ruderisch</surname> <given-names>N</given-names></name><name><surname>Deng</surname> <given-names>S</given-names></name><name><surname>Liddelow</surname> <given-names>SA</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Daneman</surname> <given-names>R</given-names></name><name><surname>Maniatis</surname> <given-names>T</given-names></name><name><surname>Barres</surname> <given-names>BA</given-names></name><name><surname>Wu</surname> <given-names>JQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex</article-title><source>Journal of Neuroscience</source><volume>34</volume><fpage>11929</fpage><lpage>11947</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1860-14.2014</pub-id><pub-id pub-id-type="pmid">25186741</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Swanson</surname> <given-names>AM</given-names></name><name><surname>Villalba</surname> <given-names>RM</given-names></name><name><surname>Guo</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Matheny</surname> <given-names>S</given-names></name><name><surname>Murakami</surname> <given-names>T</given-names></name><name><surname>Stephenson</surname> <given-names>JR</given-names></name><name><surname>Daniel</surname> <given-names>S</given-names></name><name><surname>Fukata</surname> <given-names>M</given-names></name><name><surname>Hall</surname> <given-names>RA</given-names></name><name><surname>Olson</surname> <given-names>JJ</given-names></name><name><surname>Neigh</surname> <given-names>GN</given-names></name><name><surname>Smith</surname> <given-names>Y</given-names></name><name><surname>Rainnie</surname> <given-names>DG</given-names></name><name><surname>Van Meir</surname> <given-names>EG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>BAI1 regulates spatial learning and synaptic plasticity in the Hippocampus</article-title><source>Journal of Clinical Investigation</source><volume>125</volume><fpage>1497</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1172/JCI74603</pub-id><pub-id pub-id-type="pmid">25751059</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55732.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Pera</surname><given-names>Martin</given-names></name><role>Reviewing Editor</role><aff><institution>The Jackson Laboratory</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cortes</surname><given-names>Daniel</given-names> </name><role>Reviewer</role><aff><institution>The JACKSON LABORATORY</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Noble</surname><given-names>Mark</given-names> </name><role>Reviewer</role><aff><institution>University of Rochester School of Medicine</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The authors have discovered a new pathway for regulation of neural stem cells, cells that can give rise to neurons, myelin producing cells and supporting cells of the brain. The findings may yield new approaches to brain repair using stem cell transplants.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Novel C1q receptor-mediated signaling controls neural stem cell behavior and neurorepair&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor The following individuals involved in review of your submission have agreed to reveal their identity: Daniel Cortes (Reviewer #2); Mark Noble (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>The study provides insight into a novel signaling mechanism based on the complement protein C1q for the control of neural stem cell migration and differentiation, findings which are highly relevant to repair in the central nervous system.</p><p>Essential revisions:</p><p>Both reviewers are very enthusiastic about the findings in this study. Reviewer 1 points to some areas in two figures that require clarification or further explanation.</p><p>When you compare the results of Figure 7I vs. Figure 8C and specifically controls, they look really different. I understand inevitable variability among experiments, but why do 123 positive cells drop abruptly out of the epicenter on Figure 8C and not on Figure 7I? I also notice that those are different values. Why is one expressed in total numbers, and the other one is expressed in percentage? That is confusing, is there a reason for that? That makes them hard to compare, but in any case, I don't think that accounts for the observed variability between the two plots. I suggest that the experiment in Figure 8C must be done with another control. The final experiment should be CD44-WT, CD44-KO, and C1q Nab + CD44WT; unless they can correct this disparity. The full reviews are enclosed for clarity.</p><p><italic>Reviewer #1:</italic></p><p>The authors have previously found that C1q modulates NSC proliferation, fate, and migration. Here they want to discover the signaling pathway for such effects. They found that five different membrane receptors bind C1q, and specific downstream proteins are phosphorylated upon the addition of C1q. The experiments support that CD44 mediates migration and gliogenesis; nonetheless, the proliferation of NSCs is a CD44-independent process. They finally found that after spinal cord injury, CD44-KO improves spinal cord injury recovery. The authors uncovered a novel signaling mechanism by which C1q modulates NSCs activity. The previous effect seems to be independent of the immune system finding new roles for C1q.</p><p>1) If you compare the results of Figure 7I vs. Figure 8C and specifically controls, they look really different. I understand inevitable variability among experiments, but why do 123 positive cells drop abruptly out of the epicenter on Figure 8C and not on Figure 7I? I also notice that those are different values. Why is one expressed in total numbers, and the other one is expressed in percentage? That is confusing, is there a reason for that? That makes them hard to compare, but in any case, I don't think that accounts for the observed variability between the two plots. I suggest that the experiment in Figure 8C must be done with another control. The final experiment should be CD44-WT, CD44-KO, and C1q Nab + CD44WT; unless they can correct this disparity.</p><p>This is a really well-conducted project, with clear goals and novel results. Overall, the paper is solid enough to support the publication after the suggested changes.</p><p><italic>Reviewer #2:</italic></p><p>It is a delight to read such a well thought out and interesting manuscript. This was a well-written, indeed a gripping, read from start to finish. The findings are fascinating, the experiments are very well conducted, and the story is artfully told.</p><p>The core of this story is that the authors previously found a non-immune role for complement C1q in modulating human neural stem cell (hNSC) migration and fate. They now have investigated the mechanism of C1q's effects, and show that it has the surprising property of being a ligand that activates intracellular signaling pathways. They identified five transmembrane C1q signaling/receptor candidates in hNSCs (CD44, GPR62, BAI1, cMET, and ADCY5). A deeper investigation revealed that CD44 mediates C1q induced hNSC signaling and chemotaxis in vitro. They also show that this pathway mediates hNSC migration and functional repair in vivo after spinal cord injury and that manipulation of this pathway can enhance the therapeutic benefits of nHSC transplantation.</p><p>The idea that C1q has non-traditional roles has been shown in previous studies by this group and others, and it is clear that there are C1q effects that are separate from complement cascade activation. These additional properties suggest that C1q is a ligand for something, but it is not known how it works in this regard.</p><p>After demonstrating that C1q activates MAP/ERK and PI3K pathways at nM concentrations, they used an unbiased screen assay to cross-link C1q to surface proteins on hNSCs. This approach yielded five candidate receptors, which were validated using elegant Proximity Ligation Assays. They next showed that inhibition of pathway activation with pharmacological inhibitors blocked effects of C1q.</p><p>They focused on CD44 due to previous indications of the effects of CD44 on ERK signaling pathways (although the same would be true for c-MET). This was a good choice, as CD44 knockout cells did not show ERK activation or stimulation of migration in response to C1q. Similar results were obtained with NSCs derived from CD44 knockout mice.</p><p>They then conducted in vivo studies and showed that CD44 knockout hNSCs show differences in their localization in traumatic SCI, differences in astrocyte generation and enhancing the ability of hNSCs to promote locomotor recovery in acute SCI. These data indicate effects of C1q in vivo. They also found spatial and temporal C1q gradients in vivo following SCI, with a distribution consistent with results of their other studies. They also showed improved motor recovery, thus demonstrating a potential therapeutic utility of their findings. C1q depletion had similar effects as CD44 knockout. This was done by injecting a C1q neutralizing antibody into the lesion center.</p><p>It is also exciting that this is likely to be the beginning of a story that will continue to become still more interesting.</p><p>As expected for this team, the data are all rock solid.</p><p>In short, this is wonderfully exciting paper. Congratulations to the authors on such a lovely piece of research.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55732.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Both reviewers are very enthusiastic about the findings in this study. Reviewer 1 points to some areas in two figures that require clarification or further explanation.</p><p>When you compare the results of Figure 7I vs. Figure 8C and specifically controls, they look really different. I understand inevitable variability among experiments, but why do 123 positive cells drop abruptly out of the epicenter on Figure 8C and not on Figure 7I? I also notice that those are different values. Why is one expressed in total numbers, and the other one is expressed in percentage? That is confusing, is there a reason for that? That makes them hard to compare, but in any case, I don't think that accounts for the observed variability between the two plots. I suggest that the experiment in Figure 8C must be done with another control. The final experiment should be CD44-WT, CD44-KO, and C1q Nab + CD44WT; unless they can correct this disparity. The full reviews are enclosed for clarity.</p></disp-quote><p>We thank the reviewer for highlighting the difference in data presentation for Figure 7I and Figure 8C. This has been addressed, and the data in Figure 7I and Figure 8C have been re-graphed to be in identical format (stereological estimate of SC123 cell number). We have modified both the text and the figure legends to include these changes in the paper.</p><p>We also note several additional points for the reviewer’s consideration. First, while the contusion injury induced was theoretically the same, these experiments were separated by a large gap in time. Second, while both experiments were conducted in constitutively immunodeficient mouse strains, these were different due to availability (Rag1 – Figure 7 and NODScid mice Figure 8). Finally, the timepoints of analysis were not identical (16 WPT Figure 7I and 12WPT Figure 8C). Accordingly, one would not expect an exact overlay between datasets – however, despite these differences, the fact that transplanted hNSC behaved similarly, including in total cell baseline engraftment (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>) does indicate that the hNSC transplants and cell behavior between these experiments was generally quite consistent.</p><fig id="sa2fig1"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55732-resp-fig1-v2.tif"/></fig></body></sub-article></article>